An open unified deep graph learning framework for discovering drug leads

Yueming Yin, Haifeng Hu, Zhen Yang, Jitao Yang, Chun Ye, Jiansheng Wu, and Wilson Wen Bin Goh

Computational discovery of ideal lead compounds is a critical process for modern drug discovery. It comprises multiple stages: hit screening, molecular property prediction, and molecule optimization. Current efforts are disparate, involving the establishment of models for each stage, followed by multistage multi-model integration. However, this is non-ideal, as clumsy integration of incompatible models increases research overheads, and may even reduce success rates in drug discovery. Facilitating compatibilities requires establishing inherent model consistencies across lead discovery stages. Towards that effect, we propose an open deep graph learning (DGL) based pipeline: generative adversarial feature subspace enhancement (GAFSE), which first unifies the modeling of these stages into one learning framework. GAFSE also offers standardized modular design and streamlined interfaces for future expansions and community support. GAFSE combines adversarial/generative learning, graph attention network, graph reconstruction network, and optimizes the classification/regression loss, adversarial/generative loss, and reconstruction loss simultaneously. Convergence analysis theoretically guarantees model generalization performance. Exhaustive benchmarking demonstrates that the GAFSE pipeline achieves excellent performance across almost all lead discovery stages, while also providing valuable model interpretability. Hence, we believe this tool will enhance the efficiency and productivity of drug discovery researchers.

Index Terms—Drug Discovery, Molecule Optimization, Deep Graph Learning, Generalization, Interpretability.

I. INTRODUCTION

C OMPUTATIONAL discovery of ideal lead compounds is a critical process in modern drug discovery [1], [2]. This involves multiple stages, including hit screening, molecular property prediction, and molecule optimization. Currently, given the availability of big data, a common approach for hit screening is to represent compound molecules as a graph structure, train a deep graph learning model and screen hits

Yueming Yin, Haifeng Hu, Zhen Yang, Jitao Yang and Chun Ye are with the School of Telecommunications and Information Engineering, Nanjing University of Posts and Telecommunications, Nanjing 210003, China.

Yueming Yin is with the School of Computer Science and Engineering, Nanyang Technological University, 637551, Singapore

Zhen Yang is with the National Engineering Research Center of Communications and Networking, Nanjing University of Posts and Telecommunications, Nanjing 210003, China.

Jiansheng Wu is with the School of Geographic and Biologic Information, and with Smart Health Big Data Analysis and Location Services Engineering Research Center of Jiangsu Province, Nanjing University of Posts and Telecommunications, Nanjing 210023, China.

Wilson Wen Bin Goh is with Lee Kong Chian School of Medicine, School of Biological Sciences, Nanyang Technological University, 637551, Singapore, and Center for Biomedical Informatics, 636921, Singapore.

Corresponding author: Yueming Yin (yinym96@qq.com), Haifeng Hu (huhf@njupt.edu.cn), Jiansheng Wu (jansen@njupt.edu.cn) and Wilson Wen Bin Goh (wilsongoh@ntu.edu.sg).



Fig. 1. Illustration of the proposed GAFSE framework.

according to their predicted bioactivities [3]. In addition to bioactivity, accurate drug discovery entails multiple molecular property prediction problems spanning multiple length scales, including physicochemical, geometric, energetic, electronic, and thermodynamic properties [4]. Given such high information modalities and complexities, training deep graph learning to predict molecular properties is a convenient and consequently, popular approach [5]. As a critical step in drug development, molecule optimization improves the desired properties of drug candidates through chemical modification. It includes the optimization of hits to leads, and the optimization of leads towards viable drug development. Currently, a popular practice is to predict potential alternative sites by deep graph learning on given molecular graphs, and perform removal and/or addition of atoms or fragments at that site. It typically includes optimizing the binding activity of hits and improving the ADMET properties of leads.

Current computational drug discovery scheme is to build discrete models for each stage followed by model integration [2]. However, clumsy comparisons across incompatible models may hamper efficiency and reduce success rates. These discrete models were developed based on different frameworks, different data, or even different computational languages. Thus, how to select and use these disparate models (for each process) becomes a challenging problem in itself. Moreover, this also leads towards problems of consistency and synergy between the multitude of machine learning models used across the myriad processes of lead discovery [6]. Our previous research found that the modeling of many processes in lead discovery was consistent in nature and could be better exploited [7], [8], [9], [10], [11]. Firstly, the objects of these processes are small compound molecules, which can be naturally represented as graph structures (deep graph learning methods can naturally be developed to model these processes). Secondly, the problems of these process studies can be abstracted into the prediction of property values of compound molecules, that is, the quantitative structure-property relationship (QSPR) problem [12]. For hit screening, we predict the relationship between compound structure and activity; for molecular property prediction, we study the relationship between compound structure and various molecular properties; for molecule optimization, we study the relationship between compound structure optimization and molecular activity and/or ADMET properties. These related objectives can be unified.

Therefore, we propose a unified learning framework to achieve better model coherence. Interestingly, despite the need, there are no other reported works in this area. Our unified learning framework is meant to: (1) Resolve difficulties in user use and secondary development; (2) Facilitate model evaluation and selection; (3) Improve model coherence across multiple processes; (4) Improve the success rate of lead discovery. Our unified deep graph learning framework is open. This brings the following benefits: (1) facilitate community participation in solution building across the myriad of lead compound discovery processes; (2) facilitate code reusability, model reproducibility and transparency via the adoption of standardized modules, streamlined interfaces, and detailed documentation.

However, unifying hit screening, molecular property prediction and molecule optimization in one framework will bring many challenges, because each of these processes has its unique characteristics. For example, some tasks are better resolved via classification methods while others are by regression learning. Within themselves, there are problems of small samples and unbalanced samples in classification learning. And in regression problems, there will be problems of activity cliffs, inconsistent distribution of training and testing samples, and small samples. Molecular optimization problems take into account the bioactivity and specificity of molecules, and thus need to optimize molecules for multiple goals. To build an open unified deep graph learning framework for discovering drug leads while also considering the specificity of these steps, this paper considers the following aspects: (1) Objective function. Various loss functions are introduced in the framework, including classification/regression/adversarial/generation, etc. (2) Small samples. Semi-supervised learning and multi-task learning are introduced in the framework. (3) Activity cliffs. Adversarial learning and generative learning are introduced in the framework. (4) Molecular optimization. In the framework, graph attention mechanism, graph reconstruction network, and matching molecular pairs on activity cliffs (MMP-Cliffs) [13] are introduced. Of course, the discovery of drug leads is complicated, and to solve it better, more learning methods need to be introduced in the future.

In this paper, we constructed an open unified deep graph learning framework GAFSE for discovering drug leads. For the screening of hit compounds, we develop the algorithm GAFSE-HS on the GAFSE framework, and its results on the GPCR benchmark dataset show that it exceeds the state-of-theart bioactivity regression algorithm AFSE [11]. For molecular property prediction, we develop the algorithm GAFSE-MP on the GAFSE framework, and its results on the ADMET benchmark dataset show that it exceeds the state-of-thearts molecular property prediction algorithm ADMETlab 2.0 [14]. For molecule optimization, we developed the algorithm GAFSE-MO on the GAFSE framework. The results on the molecule optimization dataset generated by the above benchmark datasets show that GAFSE-MO obtains precise optimization results of molecular activities and properties; and the results on the COVID-19-related dataset (AID1706 Bioassay Data) show that, GAFSE-MO also outperforms the state-of-the-arts molecular generation algorithm GEOM-CVAE [15]. In addition, the convergence of the core adversarial algorithm in our learning framework GAFSE is theoretically proved, and an adaptive learning adjustment mechanism is designed accordingly.

II. METHODS

The framework of GAFSE is shown in Figure 2a. To unify hit screening, molecular property prediction, and lead optimization openly, the GAFSE framework can be embedded between molecular features and downstream tasks in general molecular property prediction (MP) pipelines. By joining the GAFSE framework, general MP models will generate molecules with optimized properties while the model generalization is enhanced. Outside the GAFSE framework, the molecular embedding model (this paper takes Attentive FP [16] as an example, see supplementary Algorithm S1 for its implementation) produces molecular embeddings f to capture the key features of molecular graphs, and feeds them into the GAFSE framework to reconstruct the input molecules (Figure 2a: green lines). Then, the MP model fits the function between molecular embeddings and their property values through multilayer fully connected neural networks, and inputs its gradient on molecular embeddings into the GAFSE framework (Figure 2a: the input blue line of GAFSE). Inside the GAFSE framework, the adversarial subspace enhancement algorithm (Section II-B-1: AFSE) generates adversarial perturbations d based on the gradient of molecular embeddings, and enhances the generalizability of the MP model together with a theoretical adaptive learning rate (Figure 2a: the output blue line of GAFSE, detailed in Section II-C). Meanwhile, the attentive graph reconstruction networks (Section II-A: AGRNs) reconstruct the optimized molecule upon the predictable property according to the molecular embedding f and the adversarial perturbation d (Figure 2a: red lines, detailed in Section II-B). See supplementary Table S1 for the notations used in this section.

A. Attentive Graph Reconstruction Networks

The graph attention mechanism [17] has been validated in [16] to have important utility and interpretability for targeted extraction of molecular embeddings. Its interpretability is reflected in the focus on key atoms [10]. However, this is not the ultimate goal of drug discovery, and subsequent changes and optimizations on key atoms are almost the only way to develop molecular drugs. To predict possible optimization elements at key atomic positions, we propose a novel Attentive Graph Reconstruction Networks (AGRNs) to provide models for subsequent molecule optimization.



Fig. 2. a) Illustration of the proposed GAFSE framework. b) Illustration of generating MMP-Cliffs by the proposed GAFSE. "MMP-Cliffs" means matched molecular pairs, which are defined as a pair of molecules that differ only by a single chemical transformation. c) Schematic of GAFSE molecule optimization: (c-1) Graph embeddings of atoms. (c-2) Aggregation of atom embeddings and reconstruction of molecules. (c-3) The *d* generated by GAFSE is mapped onto atom embeddings. (c-4) Updates to atom embeddings. (c-5) Graph attention aggregation among atom embeddings. (c-6) Modified position and element estimated from updated atom embeddings.

The algorithm of AGRNs is shown in the supplementary Algorithm S2, which mainly includes the following key steps: (1) Feature Mapping:

$$\gamma_i = \operatorname{softmax}(\langle \mathbf{f}, \mathbf{h}_i \rangle). \tag{1}$$

To map the molecular embedding to its internal atoms, Eq. 1 maps the information contained in the molecular embedding to each atom by conducting the inner product of the molecular embedding f and atomic embeddings \mathbf{h}_i . Where $\langle \cdot \rangle$ represents the vector inner product, and "softmax" represents the Softmax activation function.

(2) Feature Updating:

$$\mathbf{g}_i = \gamma_i \mathbf{f} + \mathbf{h}_i. \tag{2}$$

To obtain the features of generated atoms, Eq. 2 updates

the hidden layer features of each atom \mathbf{h}_i by taking γ_i as the step and along the direction of the molecular embedding \mathbf{f} . (3) Feature Relating:

$$\mathbf{r}_i = \operatorname{elu}(\mathbf{W} \cdot (\operatorname{dropout}([\mathbf{f}, \mathbf{g}_i])) + \mathbf{c}). \tag{3}$$

To discover the key atomic information in the molecule, Eq. 5 perceives the relationship information \mathbf{r}_i between the hidden layer vector \mathbf{g}_i of each atom and the molecular embedding **f** through neural networks. Among them, **W** and **c** represent the weight matrix and bias vector of different neural networks (NNs); $[\cdot, \cdot]$ represents vector concatenation; "dropout" means to randomly drop some network nodes in the training batch to prevent overfitting; "elu" represents Exponential Linear Unit, which is used to activate the output of neurons nonlinearly, while retaining the nonlinear activation

atom feature	type	size	description	ϕ_a	L_a	
atom symbol	one-hot	16	[B, C, N, O, F, Si, P, S, Cl, As, Se, Br, Te, I, At, metal]	Softmax	WCE ^a	
degree	one-hot	6	number of covalent bonds [0,1,2,3,4,5]	Softmax	CE b	
formal charge	integer	1	electrical charge	/	MSE ^c	
radical electrons	integer	1	number of radical electrons	ReLU	MSE	
hybridization	one-hot	6	[sp, sp ² , sp ³ , sp ³ d, sp ³ d ² , other]	Softmax	CE	
aromaticity	binary	1	whether the atom is part of an aromatic system [0/1]	Sigmoid	CE	
hydrogens	one-hot	5	number of connected hydrogens [0,1,2,3,4]	Softmax	CE	
chirality	binary	1	whether the atom is chiral center $[0/1]$	Sigmoid	CE	
chirality type	binary	2	[R,S]	Sigmoid	CE	
bond feature	type	size	description	ϕ_b	L_b	
bond type	one-hot	4	[single, double, triple, aromatic]	Softmax	CE	
conjugation	binary	1	whether the bond is conjugated [0/1]	Sigmoid	CE	
ring	binary	1	whether the bond is in ring [0/1]	Sigmoid	CE	
stereo	one-hot	4	[StereoNone, StereoAny, StereoZ, StereoE]	Softmax	CE	
"WICE" many the weighted areas antrony loss h "CE" many areas antrony loss 6 "MSE" many many areas						

TABLE I INITIAL ATOMIC AND BOND FEATURES

^a "WCE" means the weighted cross-entropy loss. ^b "CE" means cross-entropy loss. ^c "MSE" means mean square error.

value of the negative part.

(4) Relation Readout:

$$\mathbf{g}_i^{t-1} = \operatorname{relu}(\operatorname{GRU}(\mathbf{r}_i^t, \mathbf{g}_i^t)).$$
(4)

To read out the embeddings \mathbf{g}_i^{t-1} that are closer to the initial features of the atoms, Eq. 4 is derived from the atomic current embeddings \mathbf{g}_i^t and the relation information \mathbf{r}_i^t through the Gated Recurrent Unit (GRU). "Relu" stands for Rectified Linear Unit, which is used for the output of non-linearly activated neurons.

(5) Attention:

$$w_{N(i)} = \text{softmax}(\text{leaky_relu}(\mathbf{W} \cdot \text{dropout}([\mathbf{g}_i^l, \mathbf{g}_{N(i)}^l]) + \mathbf{c})).$$
(5)

To focus on neighboring atoms that are critical to inferring initial features, Eq. 5 gets the attention weight $w_{N(i)}$ between each atom *i* and its adjacent atoms N(i) by one-layer NNs. Among them, the initial values of \mathbf{g}_i^l and $\mathbf{g}_{N(i)}^l$ come from $\mathbf{g}_i^{t=0}$ and $\mathbf{g}_{N(i)}^{t=0}$ in Eq. 4. (6) Aggregation:

$$\mathbf{C}_{i}^{l} = \operatorname{elu}(\sum_{N(i)} w_{N(i)} \cdot \mathbf{W}(\operatorname{dropout}(\mathbf{g}_{N(i)}^{l})) + \mathbf{c}).$$
(6)

To assist in inferring the initial features of atoms and bonds, Eq. 6 aggregates the context feature of each atom. (7) Context Readout:

$$\mathbf{g}_{i}^{l-1} = \operatorname{relu}(\operatorname{GRU}(\mathbf{C}_{i}^{l}, \mathbf{g}_{i}^{l})).$$
(7)

To approximate the initial features, Eq. 7 deduces the hidden feature on each atom by GRU. (8) Context Updating:

$$\mathbf{g}_{N(i)}^{l} = \text{leaky_relu}(\mathbf{W} \cdot \text{dropout}([\mathbf{g}_{i}^{l-1}, \mathbf{g}_{N(i)}^{l-1}]) + \mathbf{c}).$$

For the next round of inference, Eq. 8 updates the adjacent features for each atom by one-layer NNs. (9) Generating:

$$\hat{\mathbf{a}}_i = \phi_a (\mathbf{W} \cdot \mathbf{g}_i^0 + \mathbf{c}), \tag{9}$$

(8)

$$\hat{\mathbf{b}}_{i,j} = \phi_b(\text{leaky_relu}(\mathbf{W} \cdot \text{dropout}([\mathbf{g}_i^0, \mathbf{g}_j^0]) + \mathbf{c})). \quad (10)$$

To generate the molecular graph, Eq. 9 and 10 predict the initial features of each atom and bond respectively through neural networks and an activation function. In Eq. 9 and 10, ϕ_a and ϕ_b map the hidden embeddings to the initial features of atoms and bonds, respectively. The definitions of initial features of atoms and bonds are shown in table I.

Denote AGRNs as a graph decoder G, and its function to generate molecular graphs can be expressed as follows:

$$G: \{\mathbf{f}, \ \mathcal{H}\} \to \{\hat{\mathbf{a}}_i, \ \mathcal{B}_i\}_{i=1}^{N_a},$$

where $\mathcal{H} = \{\mathbf{h}_i\}_{i=1}^{N_a}, \ \mathcal{B}_i = \{\hat{\mathbf{b}}_{i,j}\}_{j=1}^{N(i)},$ (11)

where N_a represents the number of atoms contained in the molecule, and N(i) represents the number of the adjacent atoms of the *i*-th atom.

B. Generative Adversarial Feature Subspace Enhancement

1) Adversarial Feature Subspace Enhancement (AFSE) Algorithm: AFSE was first proposed by us in [11] to enhance the model generalization for regression learning of molecular bioactivities. This paper extends AFSE to enhance model generalization for both regression and classification learning:

$$\begin{split} \mathcal{L}_{\text{AFSE}}(\mathbf{f}, \mathbf{N}, \mathbf{d}) &:= D(\mathbf{N}(\mathbf{f}, \mathbf{f}), \mathbf{N}(\mathbf{f}, \mathbf{f} \oplus \mathbf{d})), \\ \text{where } \mathbf{d} &= \eta \frac{\mathbf{g}}{\|\mathbf{g}\|}, \mathbf{g} = \nabla_{\mathbf{r}} D(\mathbf{N}(\mathbf{f}, \mathbf{f}), \mathbf{N}(\mathbf{f}, \mathbf{f} \oplus \mathbf{r}))|_{\|\mathbf{r}\| \leq \varepsilon}, \\ D(\mathbf{N}(\mathbf{f}, \mathbf{f}), \mathbf{N}(\mathbf{f}, \mathbf{f} \oplus \mathbf{r})) &\triangleq [\sigma(\frac{\mathbf{N}(\mathbf{f}, \mathbf{f} + \mathbf{r}) + \varepsilon}{\mathbf{N}(\mathbf{f}, \mathbf{f}) + \varepsilon}) - \gamma]^2 \\ &+ [\sigma(\frac{\mathbf{N}(\mathbf{f}, \mathbf{f} - \mathbf{r}) + \varepsilon}{\mathbf{N}(\mathbf{f}, \mathbf{f}) + \varepsilon}) - \gamma]^2, \\ \mathbf{N}(\mathbf{f}, \mathbf{f}) &:= \text{Property}, \\ \mathbf{f} &= \mathbf{E}(\mathbf{m}), \end{split}$$
(12)

where **m** is the initial graph representation of the molecule, **f** is the molecular embedding obtained by the graph learning model E according to **m**, N is the neural network for downstream property regression or classification, **r** is a Gaussian random vector, η is the learning rate, ε is a small positive real number, σ is the sigmoid function, $\gamma = \sigma(1)$ is used for the standardized discrepancy function $D(\cdot, \cdot)$. The adversarial perturbation d generated in Eq. 12 can significantly change the predicted property. After maximizing N and minimizing the AFSE loss for E, E can extract more smooth embeddings for molecules with similar activity values but large structural differences to enhance generalization. At the same time, N can obtain the ability to perceive the effect of small changes in molecular embedding on the activity value. Therefore, the adversarial perturbation d obtained by Eq. 12 is an estimate of the potentially highly active molecular embedding $\mathbf{f} + \mathbf{d}$.

2) Molecular Graph Reconstruction: Chemically, the fine-tuned molecules with significantly improved activity form matched molecular pairs with the original molecules, which are of great significance to the study of the activity cliff and the optimization of molecules. The most common chemical transformation is to modify a chemical element at an atomic site, perhaps the embedding f+d of a potentially highly active molecule can lead us to intervene in a key atomic site for a replacement element. To this end, we use the AGRNs proposed in the previous section to reconstruct the molecule from f; then find the key atomic positions and predict new chemical elements from f + d, which may optimize the property of the whole molecules. We design the reconstruction loss function to achieve this goal:

$$\mathcal{L}_{Recon.}(\hat{\mathbf{a}}_{i}, \mathbf{a}_{i}, \hat{\mathbf{b}}_{i,j}, \mathbf{b}_{i,j}) := \frac{1}{N_{a}} \sum_{i=1}^{N_{a}} \left[L_{a}(\hat{\mathbf{a}}_{i}, \mathbf{a}_{i}) + \sum_{j \in N(i)} L_{b}(\hat{\mathbf{b}}_{i,j}, \mathbf{b}_{i,j}) \right], \quad (13)$$

where L_a is the error function between reconstructed initial feature $\hat{\mathbf{a}}_i$, $\hat{\mathbf{b}}_{i,j}$ and the true initial feature \mathbf{a}_i and $\mathbf{b}_{i,j}$ (see Table I). The adjacent atom indexer N(i) returns the atom index adjacent to the *i*-th atom.

It should be noted that, the content of various elements in natural molecules varies evidently, forming a priori distribution of chemical elements. Therefore, elements are weighted according to the proportion of atoms in each molecule when calculating the cross-entropy loss of node classification (denote as "WCE" in Table I and used as L_a in Eq. 13). Specifically, the initial atom feature $\mathbf{a}_{i,k} = 0/1$ can be expressed as whether the *i*-th atom belongs to the *k*-th element, and the reconstruction probability $\hat{\mathbf{a}}_{i,k} \in [0,1]$ measures the probability of the *i*th atom belonging to the *k*-th element. Then their weighted cross-entropy loss can be defined as:

WCE
$$(\hat{\mathbf{a}}_{i,k}, \mathbf{a}_{i,k}) := -\sum_{i=1}^{N_a} (1 - \frac{N_{k^*(i)}}{N_a}) \cdot \text{CE}(\hat{\mathbf{a}}_i, \mathbf{a}_i),$$

where $k^*(i) = \arg\max_{i,k} \mathbf{a}_{i,k},$ (14)

In Eq. 14, the initial element indexer $k^*(i)$ is a function of the atom index i. N_{k^*} represents the number of the k^* -th element contained in all N_a atoms. "CE" denotes the cross-entropy loss.

3) Molecular Graph Optimization: To provide stronger interpretability, the molecule optimization in this paper utilizes graph node classification logic to change the element symbols of one single atom at one time, forming matched molecular pairs on the activity cliff (MMP-Cliffs) [13]. Therefore, the MMP-Cliffs generation scheme of GAFSE is illustrated in Figure 2b. As shown, the binding sites of drug molecules to targets are often concentrated in a few key atomic sites, which usually have unique topological relationships relative to other atomic sites. Therefore, we first determine the key atomic positions through the distribution of posterior probabilities. Let P(s|a) be the posterior probability that the atom a is predicted to be the chemical element s, which can be estimated by the molecular embedding \mathbf{f} , the atomic embedding set \mathcal{H} , the graph decoder $\mathbf{G} : \mathbb{R}^{d_f} \times \mathbb{R}^{N_a \times d_f} \to [0, 1]^{N_a \times N_s}$ and the d generated by the AFSE algorithm:

$$P_{\mathbf{f}+\mathbf{d}}(s|a) := \mathbf{G}(\mathbf{f} + \text{Stopgrad}(\mathbf{d}), \mathcal{H})[a][s] = \widetilde{\mathbf{a}}_{i=a,k=s},$$

$$a = 1, 2, \cdots, N_a, \ s = 1, 2, \cdots, N_s,$$

(15)

where "Stopgrad(·)" means to stop the propagation of the gradient, N_a denotes the number of atoms, and d_f denotes the dimension of the embedded features for both molecules and atoms. The number of element types N_s is equal to 16, corresponding to the 1st to 16th dimension features of the atoms defined in Table I. Then the key atomic position a^* can be determined according to the maximum posterior probability criterion:

$$a^* = \arg\max_{a} \left(\max_{s \notin S_a} P_{\mathbf{f}+\mathbf{d}}(s|a) \right),$$

where $S_a := \{s | P_{\mathbf{f}}(s|a) \ge P_0\}.$ (16)

In Eq. 16, the conditional probability $P_{\mathbf{f}}(s|a)$ refers to the reconstruction probability $\hat{\mathbf{a}}_{i=a,k=s}$. Therefore, the set S_a represents the set of chemical elements at the *a* atomic position predicted by graph generator G on the original molecular feature \mathbf{f} , whose probability is greater than the threshold P_0 . According to our previous research [18], [19], [20], after G is well trained, S_a usually contains initial elements and their confusing elements. Therefore, we hope to avoid the interference of these elements in the generation of new elements, i.e., let $s \notin S_a$. Then, we determine the replaced element s^* according to the maximum posterior probability criterion and the activation threshold P_0 :

$$s^* = \operatorname*{arg\,max}_{s \in \mathcal{S}^*_a} P_{\mathbf{f}+\mathbf{d}}(s|a^*),$$
where $\mathcal{S}^*_a := \{s|P_{\mathbf{f}+\mathbf{d}}(s|a^*) \ge P_0, s \neq s^0\}.$
(17)

In Eq. 17, the candidate set S_a^* is the set of replaceable elements at atomic position a^* . Outside the candidate set S_a^* , the correspond a^* atom of $\max_s P_{\mathbf{f}+\mathbf{d}}(s|a^*) < P_0$ is not optimized to reduce the influence of low-confidence optimization on the result accuracy. Overall, a schematic diagram of GAFSE molecule optimization is shown (see Figure 2c), and its implementation can be found in the supplementary Algorithm S3.

4) Validity Optimization of Generated Molecules: The composition of molecules should conform to chemical specifications, so elements need to be verified for their validity when they are modified. To this end, this paper designs a novel mask-based validity optimization objective:

$$\mathcal{L}_{Val.}(a^*, s^*) := -\frac{1}{N_a} \sum_{i=1}^{N_a} (1 - \operatorname{Val}(s_i^* | a_i^*)) \cdot \log(1 - P_{\mathbf{f} + \mathbf{d}}(s_i^* | a_i^*))$$
(18)

In Eq. 18, the validity function $\operatorname{Val}(s_i^*|a_i^*)$ judges the chemical

validity (1: valid, 0: invalid) of the optimized element a_i^* (Eq. 16) on selected atom s_i^* (Eq. 17) from the *i*-th molecule, and filter invalid molecules to calculate this validity loss. The probability $P_{\mathbf{f}+\mathbf{d}}(s_i^*|a_i^*)$ is defined by Eq. 15.

5) Generative Adversarial Feature Subspace Enhancement (GAFSE) Algorithm: Finally, GAFSE presents four optimization objectives: (1) biological property objective $\mathcal{L}_{Bio.}$, (2) AFSE objective \mathcal{L}_{AFSE} , (3) reconstruction objective $\mathcal{L}_{Recon.}$ and (4) validity objective $\mathcal{L}_{Val.}$. In total, its optimization problem can be formulated as:

$$\underset{E,N,G}{\min} \max_{\mathbf{d}} \underbrace{\mathcal{L}_{Bio.} + \lambda_1 \mathcal{L}_{AFSE}}_{Representation \ Learning} + \lambda_2 \underbrace{(\mathcal{L}_{Recon.} + \mathcal{L}_{Val.})}_{Molecular \ Optimization} ,$$
where $\mathcal{L}_{Bio.} := \operatorname{Error}(N(\mathbf{f}, \mathbf{f}), \ Assay),$

$$(19)$$

where "Assay" represents the molecular activity or property value determined by chemical wet experiments; $Error(\cdot, Assay)$ represents the error function between predictions and assays, that is, the cross-entropy loss for classification assays or the mean square error for regression assays; The coefficient λ_1 balances the biological property loss and the AFSE loss, while λ_2 balances the representation learning and the molecule optimization.

C. Convergence guarantee on representation learning

To theoretically analyze the representation learning of the GAFSE framework, we performed a convergence analysis on it. Firstly, one layer of Neural Networks (NNs) with multiple outputs (or one output) can be composed of a weight matrix W (or vector \mathbf{a}) and \mathbf{a} bias vector \mathbf{c} (or variable c). For a clearer analysis, we omit the writing of the bias c and the constant γ (Eq. 12) in the following derivation. Note that the weight matrix W (or vector a) is irreducible after omitting the bias c. Two dimensionality reduction matrices W_1 and W_2 are introduced to map the two features f and f + d to half of the input dimension of a, respectively. Suppose the feature vector extracted by Network is f, the biological property assay is y, and the object of representation learning can be written as

$$\begin{split} \min_{\mathbf{a},\mathbf{W}_{1},\mathbf{W}_{2}} & \underbrace{\left(\mathbf{a}[\mathbf{W}_{1},\mathbf{W}_{2}]\mathbf{f}-y\right)^{2}}_{\mathcal{L}_{Bio.}} \\ + \underbrace{\sigma\left(\frac{\mathbf{a}[\mathbf{W}_{1}\mathbf{f},\mathbf{W}_{2}(\mathbf{f}+\mathbf{d})]}{\mathbf{a}[\mathbf{W}_{1},\mathbf{W}_{2}]\mathbf{f}}\right) + \sigma\left(\frac{\mathbf{a}[\mathbf{W}_{1}\mathbf{f},\mathbf{W}_{2}(\mathbf{f}-\mathbf{d})]}{\mathbf{a}[\mathbf{W}_{1},\mathbf{W}_{2}]\mathbf{f}}\right)}_{\mathcal{L}_{AFSE}} \\ \text{where } \sigma(x) &= \left(\frac{1}{1+e^{-x}}-1\right)^{2} = \left(\frac{e^{-x}}{1+e^{-x}}\right)^{2} \\ \mathbf{d} &= \nabla_{\mathbf{r}} \ \sigma\left(\frac{\mathbf{a}[\mathbf{W}_{1}\mathbf{f},\mathbf{W}_{2}(\mathbf{f}+\mathbf{r})]}{\mathbf{a}[\mathbf{W}_{1},\mathbf{W}_{2}]\mathbf{f}}\right) + \sigma\left(\frac{\mathbf{a}[\mathbf{W}_{1}\mathbf{f},\mathbf{W}_{2}(\mathbf{f}-\mathbf{r})]}{\mathbf{a}[\mathbf{W}_{1},\mathbf{W}_{2}]\mathbf{f}}\right) \\ \mathbf{r} \sim N(\mathbf{0},\mathbf{1}), \end{split}$$
(20)

where $[\cdot, \cdot]$ means vector concatenation. The activation function $\sigma(x)$ we defined in the above formula is differentiable, and its derivative can be expressed by itself as

$$\sigma'(x) = \frac{2e^{-2x}}{(1+e^{-x})^2} \left(\frac{e^{-x}}{1+e^{-x}} - 1\right) = 2\sigma(x)(\sqrt{\sigma(x)} - 1).$$
(21)

According to Eq. 20, the gradient d can be simplified to

$$\mathbf{d} = \frac{\mathbf{a}\mathbf{W}_2}{\mathbf{a}[\mathbf{W}_1, \mathbf{W}_2]\mathbf{f}} (\sigma'(\frac{\mathbf{a}[\mathbf{W}_1\mathbf{f}, \mathbf{W}_2(\mathbf{f} + \mathbf{r})]}{\mathbf{a}[\mathbf{W}_1, \mathbf{W}_2]\mathbf{f}}) - \sigma'(\frac{\mathbf{a}(\mathbf{W}_1\mathbf{f} + \mathbf{W}_2(\mathbf{f} - \mathbf{r}))}{\mathbf{a}[\mathbf{W}_1, \mathbf{W}_2]\mathbf{f}})).$$
(22)

According to Eq. 20, there is $0 < \sigma(x) < 1$ for any x. Then according to Eq. 21, it has $-2 < \sigma'(x) < 0$ for any x. Therefore, the gradient d satisfies

$$\frac{-2\mathbf{a}\mathbf{W}_2}{\mathbf{a}[\mathbf{W}_1,\mathbf{W}_2]\mathbf{f}} < \mathbf{d} < \frac{2\mathbf{a}\mathbf{W}_2}{\mathbf{a}[\mathbf{W}_1,\mathbf{W}_2]\mathbf{f}}. \tag{23}$$

After the gradient d is calculated, the gradient generated from f is cleared. Therefore, when the gradient of f for Eq. 20 is calculated, d is regarded as a constant. Then, we have

$$\nabla_{\mathbf{f}} \mathcal{L}_{AFSE} = -\frac{\mathbf{a} \mathbf{W}_{2} \nabla}{\mathbf{f}^{2}} (\sigma'(\frac{\mathbf{a} [\mathbf{W}_{1}\mathbf{f}, \mathbf{W}_{2}(\mathbf{f} + \mathbf{d})]}{\mathbf{a} [\mathbf{W}_{1}, \mathbf{W}_{2}]\mathbf{f}}) + \sigma'(\frac{\mathbf{a} [\mathbf{W}_{1}\mathbf{f}, \mathbf{W}_{2}(\mathbf{f} - \mathbf{d})]}{\mathbf{a} [\mathbf{W}_{1}, \mathbf{W}_{2}]\mathbf{f}})).$$
(24)

Similarly, according to Eq. 23, $\nabla_{\mathbf{f}} \mathcal{L}_{AFSE}$ satisfies

$$\frac{-8\mathbf{a}^2\mathbf{W}_2^2}{\mathbf{a}[\mathbf{W}_1,\mathbf{W}_2]\mathbf{f}^3} < \nabla_{\mathbf{f}}\mathcal{L}_{\mathrm{AFSE}} < \frac{8\mathbf{a}^2\mathbf{W}_2^2}{\mathbf{a}[\mathbf{W}_1,\mathbf{W}_2]\mathbf{f}^3}. \tag{25}$$

For any two features f_1 and f_2 , we have

$$\begin{aligned} \|\nabla_{\mathbf{f}_{1}}\mathcal{L}_{AFSE} - \nabla_{\mathbf{f}_{2}}\mathcal{L}_{AFSE}\| &< \|\frac{8\mathbf{a}^{2}\mathbf{W}_{2}^{2}}{\mathbf{a}[\mathbf{W}_{1},\mathbf{W}_{2}]}(\frac{1}{\mathbf{f}_{1}^{3}} - \frac{1}{\mathbf{f}_{2}^{3}})\| \\ &= \|\frac{8\mathbf{a}^{2}\mathbf{W}_{2}^{2}(\mathbf{f}_{1}^{2} + \mathbf{f}_{1}\mathbf{f}_{2} + \mathbf{f}_{2}^{2})}{\mathbf{a}[\mathbf{W}_{1},\mathbf{W}_{2}]\mathbf{f}_{1}^{3}\mathbf{f}_{2}^{3}}(\mathbf{f}_{1} - \mathbf{f}_{2})\|. \end{aligned}$$
(26)

Features are normalized, so it has $\|\mathbf{f}_1\| = \|\mathbf{f}_2\| = 1$. According to the triangle inequality, Eq. 26 can be further simplified to

$$\|\nabla_{\mathbf{f}_{1}}\mathcal{L}_{AFSE} - \nabla_{\mathbf{f}_{2}}\mathcal{L}_{AFSE}\| < \|\frac{24\mathbf{a}^{2}\mathbf{W}_{2}^{2}}{\mathbf{a}[\mathbf{W}_{1},\mathbf{W}_{2}]}\| \cdot \|\mathbf{f}_{1} - \mathbf{f}_{2}\| \triangleq \beta_{AFSE}\|\mathbf{f}_{1} - \mathbf{f}_{2}\|.$$
(27)

Similarly, for \mathcal{L}_{Bio} , there is

$$\|\nabla_{\mathbf{f}_{1}} \mathcal{L}_{Bio.} - \nabla_{\mathbf{f}_{2}} \mathcal{L}_{Bio.} \| < \|2\mathbf{a}^{2} [\mathbf{W}_{1}, \mathbf{W}_{2}]^{2} \| \cdot \|\mathbf{f}_{1} - \mathbf{f}_{2} \|$$

$$\triangleq \beta_{Bio.} \|\mathbf{f}_{1} - \mathbf{f}_{2} \|.$$
(28)

Here, $\nabla_{\mathbf{f}} \mathcal{L}_{AFSE}$ and $\nabla_{\mathbf{f}} \mathcal{L}_{Bio.}$ are functions of \mathbf{f} . According to the triangle inequality [21], $\mathcal{L}_{Bio.} + \mathcal{L}_{AFSE}$ is *Lipschitz continous* [22] on $\mathcal{F} = {\mathbf{f} \in \mathbb{R}^{d_f} : ||\mathbf{f}|| = 1}$ with the *Lipschitz constent* of $\beta_{AFSE} + \beta_{Bio.}$. That is, for all $\mathbf{f_1}, \mathbf{f_2} \in \mathcal{F}$, it has

$$\begin{aligned} \|\nabla_{\mathbf{f}_{1}}(\mathcal{L}_{AFSE} + \mathcal{L}_{Bio.}) - \nabla_{\mathbf{f}_{2}}(\mathcal{L}_{AFSE} + \mathcal{L}_{Bio.})\| \\ &\leq \|\nabla_{\mathbf{f}_{1}}\mathcal{L}_{AFSE} - \nabla_{\mathbf{f}_{2}}\mathcal{L}_{AFSE}\| + \|\nabla_{\mathbf{f}_{1}}\mathcal{L}_{Bio.} - \nabla_{\mathbf{f}_{2}}\mathcal{L}_{Bio.}\| \quad (29) \\ &< (\beta_{AFSE} + \beta_{Bio.})\|\mathbf{f}_{1} - \mathbf{f}_{2}\|. \end{aligned}$$

Let f_t be the learnable feature at t-th optimization step. Then \mathbf{f}_{t+1} can be updated by

$$\mathbf{f}_{t+1} \leftarrow \mathbf{f}_t - \eta \nabla_{\mathbf{f}_t} (\mathcal{L}_{\text{AFSE}} + \mathcal{L}_{Bio.}), \tag{30}$$



Fig. 3. **a**. The regulation and control of GAFSE-HS learning rate penalty factor $\|\nabla_f \mathcal{L}_{Bio.}\|$ for model optimization. "(\uparrow)" means larger is better and vice versa. **b**. Legend for model optimization diagram. **c**. Larger $\|\nabla_f \mathcal{L}_{Bio.}\|$ forces the model to skip local sub-optima. **d**. A smaller $\|\nabla_f \mathcal{L}_{Bio.}\|$ allows the model to converge to a local or possibly global optima. **e**. Larger $\|\nabla_f \mathcal{L}_{Bio.}\|$ encourages the model to find other potential global optima.

where η is the learning rate. According to Eq. 29, it has

$$\begin{split} \|\nabla_{\mathbf{f}_{t+1}}(\mathcal{L}_{AFSE} + \mathcal{L}_{Bio.}) - \nabla_{\mathbf{f}_{t}}(\mathcal{L}_{AFSE} + \mathcal{L}_{Bio.})\| \\ &= \frac{1}{\eta} \|\eta \nabla_{\mathbf{f}_{t+1}}(\mathcal{L}_{AFSE} + \mathcal{L}_{Bio.}) - \eta \nabla_{\mathbf{f}_{t}}(\mathcal{L}_{AFSE} + \mathcal{L}_{Bio.})\| \\ &= \frac{1}{\eta} \|\mathbf{f}_{t+2} - \mathbf{f}_{t+1} + \mathbf{f}_{t+1} - \mathbf{f}_{t}\| \\ &= \frac{1}{\eta} \|\mathbf{f}_{t+2} - \mathbf{f}_{t}\| \\ &< (\beta_{AFSE} + \beta_{Bio.}) \|\mathbf{f}_{t+1} - \mathbf{f}_{t}\|. \end{split}$$
(31)

Then,

$$\|\mathbf{f}_{t+2} - \mathbf{f}_{t}\| < \eta(\beta_{\text{AFSE}} + \beta_{\text{Bio.}}) \|\mathbf{f}_{t+1} - \mathbf{f}_{t}\|.$$
(32)

Suppose \mathbf{f}^* be the global optimal solution. If $\mathbf{f}_t = \mathbf{f}^*$, when $\eta < \frac{1}{\beta_{AFSE} + \beta_{Bio.}}$, Eq. 20 has convergence:

$$\|\mathbf{f}_{t+2} - \mathbf{f}^*\|^2 < \|\mathbf{f}_{t+1} - \mathbf{f}^*\|^2.$$
(33)

If $f_t \neq f^*$, a larger learning rate, $\eta > \frac{1}{\beta_{AFSE} + \beta_{Bio.}}$, should be employed to encourage f_{t+1} stay away from f_t :

$$\|\mathbf{f}_{t+2} - \mathbf{f}_t\|^2 < L_f \|\mathbf{f}_{t+1} - \mathbf{f}_t\|^2$$
, where $L_f > 1$. (34)

To this end, we define the learning rate η of \mathbf{a} , $\mathbf{W_1}$ and $\mathbf{W_2}$ as:

$$\eta = \begin{cases} \eta^* + \alpha \|\nabla_{\mathbf{f}} \mathcal{L}_{Bio.}\| - o(\eta^*), & \eta^* < \eta_{max} \\ \eta_{max}, & \eta^* \ge \eta_{max} \end{cases}, \quad (35)$$

where $\eta^* = \frac{1}{\beta_{AFSE} + \beta_{Bio.}}$. η_{max} is the maximum learning rate used to stabilize the model parameters. α is the balance coefficient. When the gradient of biological property loss decays to $o(\eta^*)/\alpha$, it can be considered that $\mathbf{f_t}$ approximates $\mathbf{f^*}$. Then, we have $\eta \leq \eta^*$ according to Eq. 35, that is, Eq. 20 converges.

When calculating Eq. 35, the learning rate η needs to be determined before the backward propagation to update the network parameters, so we need to calculate β_{AFSE} and $\beta_{Bio.}$ in the forward propagation of the neural network to ensure the convergence of GAFSE. To this end, we use the unit vector 1 and the zero vector 0 to derive the operation of the neural network parameters, namely β_{AFSE} and $\beta_{Bio.}$ can be calculated as:

$$\beta_{\text{AFSE}} = \|\frac{24 \cdot (\mathbf{a}^T \times [\mathbf{W}_1, \mathbf{W}_2] \times [\mathbf{0}, \mathbf{1}])^2}{\mathbf{a}^T \times [\mathbf{W}_1, \mathbf{W}_2] \times [\mathbf{1}, \mathbf{1}]}\|^2, \qquad (36)$$

$$\beta_{\text{Bio.}} = 4 \cdot \|\mathbf{a}^T \times [\mathbf{W_1}, \mathbf{W_2}] \times [\mathbf{1}, \mathbf{1}]\|^4.$$
(37)

In each step of updating the neural network parameters by statistical gradient descent on $\mathcal{L}_{Bio.}$ and \mathcal{L}_{AFSE} , Eq. 35, 36 and 37 determine the learning rate η to ensure the convergence of the representation learning on **f**.

III. EXPERIMENTS

A. Screening of highly active molecules

Setup: To validate the ability of GAFSE to screen highly active molecules in compound databases, we evaluate the virtual screening performance of GAFSE on the benchmark dataset constructed in [11]. Meanwhile, to validate whether the convergence learning rate η in Eq. 35 encourages the AFSE method to converge to a better solution, we only take the "representation learning" part of Eq. 19, degenerating it an improved method of AFSE (GAFSE-HS), and compare their performance in this section. Furthermore, we found that the model works stably when the balance coefficients in Eq. 19 and Eq. 35 are taken as 0.6, 0.3, and 0.06. Therefore, we fixed $\lambda_1 = 0.6$, $\lambda_2 = 0.3$ and $\alpha = 0.06$ in all subsequent



Fig. 4. Location of GAFSE-generated molecules in the predicted structural feature-activity space for binding to the orexins receptor O43614 from the UniProt database. The red arrow indicates that the predicted activity value of the generated molecule is higher than that of their original molecules, and the blue arrow is the opposite. **b-e**. The generated true MMP-Cliffs in the dataset.

 TABLE II

 Comparison of ligand-based virtual screening indexes on benchmark datasets [11]. Baseline results are taken from [11].

Dataset size	Task ID		EF _{10%} (%)	(†)		r^2 (\uparrow)			RMSE ()		$\tau_B (\uparrow)$	
Dataset size	(Bias ↑)	AFSE	GAFSE-HS	GAFSE-MO	AFSE	GAFSE-HS	GAFSE-MO	AFSE	GAFSE-HS	GAFSE-MO	AFSE	GAFSE-HS	GAFSE-MO
	1	38.46	26.92	26.92	0.4347	0.4564	0.4621	0.6619	0.6112	0.6058	0.0772	0.0508	0.0491
	2	27.78	44.44	44.44	0.1030	0.1187	0.1485	0.6618	0.9844	0.8089	0.3794	0.4624	0.4480
	3	57.89	52.63	63.16	0.2774	0.4106	0.4399	1.0085	0.8595	0.8347	0.2671	0.4310	0.4437
small	4	62.50	65.62	62.50	0.4660	0.4648	0.4508	0.7126	0.6854	0.6980	0.3986	0.3898	0.3952
	5	53.85	53.85	46.15	0.6423	0.6241	0.6256	0.7391	0.8315	0.7595	0.4222	0.3883	0.3774
	6	38.46	53.85	61.54	0.2022	0.4563	0.4490	0.8763	0.9631	0.9306	0.4116	0.4435	0.4513
	7	64.29	71.43	71.43	0.5079	0.5898	0.5842	0.8799	0.8081	0.7754	0.5293	0.5085	0.5249
	8	68.24	69.41	67.06	0.6201	0.6050	0.6068	0.8900	0.9150	0.9066	0.5783	0.5711	0.5842
	9	37.00	34.00	35.00	0.5018	0.5177	0.5292	0.5764	0.5675	0.5623	0.2823	0.2597	0.2668
	10	44.23	50.00	51.92	0.5102	0.5158	0.4980	0.7379	0.7104	0.7212	0.2915	0.3680	0.3546
	11	47.54	47.54	49.18	0.3669	0.3445	0.3979	0.9792	0.9381	0.8959	0.3113	0.3043	0.3307
	12	52.87	51.72	56.32	0.5926	0.5954	0.5887	0.9182	0.9353	0.9469	0.4318	0.4414	0.4410
Median	13	46.94	52.04	51.02	0.3702	0.3285	0.4020	0.8425	0.8932	0.8628	0.4641	0.4628	0.4569
	14	74.32	71.62	75.68	0.6144	0.5936	0.6057	0.9802	1.0619	1.0112	0.3908	0.4092	0.4203
	15	40.74	37.04	37.04	0.3943	0.4369	0.3895	0.8969	0.8316	0.8640	0.2056	0.2031	0.1679
	16	69.39	66.33	65.31	0.6416	0.5926	0.5870	0.7186	0.8366	0.8331	0.4410	0.4051	0.4001
	17	62.92	51.69	59.55	0.3032	0.2124	0.2849	0.9487	0.9273	0.9295	0.5322	0.5150	0.5338
	18	64.94	55.84	58.44	0.5766	0.5473	0.5682	0.8008	0.8389	0.8315	0.4414	0.4153	0.4299
	19	63.41	65.85	65.85	0.5188	0.5318	0.5318	0.6612	0.6503	0.6503	0.6701	0.6677	0.6677
	20	65.85	65.04	65.04	0.5152	0.6504	0.5664	0.6918	0.7088	0.6546	0.4422	0.4507	0.4694
	21	61.34	57.14	56.30	0.5173	0.5284	0.5195	0.7244	0.7071	0.7201	0.4716	0.7071	0.4583
	22	57.35	63.24	63.24	0.5291	0.5343	0.5062	0.7201	0.7299	0.7553	0.4071	0.4098	0.4048
	23	58.02	61.83	62.60	0.5674	0.5661	0.5645	0.7491	0.7579	0.7560	0.4833	0.4899	0.4919
	24	62.59	64.03	69.06	0.6161	0.5994	0.6288	0.7799	0.8024	0.7870	0.5676	0.5434	0.5666
	25	68.66	63.43	66.42	0.7110	0.5700	0.5779	0.5991	0.7451	0.7364	0.4271	0.3970	0.4220
Large	26	67.61	69.01	67.61	0.5809	0.5838	0.5371	0.7079	0.7528	0.7797	0.5061	0.5301	0.5370
8-	27	60.75	58.88	59.81	0.5522	0.5684	0.5484	0.8023	0.7006	0.7127	0.5230	0.5108	0.4972
	28	50.00	57.50	53.75	0.4087	0.4901	0.4714	0.7009	0.6441	0.6811	0.3758	0.6441	0.4100
	29	63.70	62.22	57.04	0.6177	0.6222	0.5415	0.7059	0.7884	0.7768	0.3253	0.3077	0.2908
	30	43.75	60.71	41.07	0.3941	0.6071	0.4086	0.9048	0.8987	0.8923	0.2898	0.3766	0.2390
	31	53.01	51.20	48.19	0.4972	0.4112	0.4190	0.7193	0.7622	0.7583	0.3337	0.3064	0.3005
	32	61.54	61.54	62.82	0.5883	0.6665	0.6148	0.8863	0.6665	0.8616	0.3519	0.3851	0.3702
	33	58.55	54.40	56.48	0.5025	0.5440	0.5614	0.6984	0.6594	0.6840	0.3076	0.6594	0.3214
	Average	56.01	56.73	56.91	0.4922	0.5116	0.5035	0.7843	0.7931	0.7874	0.4042	0.4368	0.4098

experiments. To reduce the computational cost, experiments in this paper omit the reconstruction loss except for atomic symbols, which are optimized for molecule optimization. iments in the hit screening (HS) stage of lead discovery, referred to as GAFSE-HS. The pipeline of GAFSE-HS is as follows: First, molecules are input into the molecular embedding model E in the form of graphs to obtain molecular

Algorithm Review: This section is about GAFSE exper-

embeddings **f**; then **f** is input to the downstream task model N to output predicted bioactivity values \hat{y} . In the training phase of GAFSE-HS, the output \hat{y} participates in the optimization of the "representation learning" part of Eq. 19, thereby updating model parameters of E and N. In the testing phase of GAFSE-HS, the output \hat{y} is used to screen out highly active molecules to complete the HS task. In this section, the performance of GAFSE-MO (introduced in Section III-B: Algorithm Review) on the HS task is additionally carried out to explore the impact of molecule optimization on representation learning.

Results: Taking the lysolipids receptor Q99500 in the UniProt database as an example, Figure 3 shows the change in GAFSE-HS learning rate penalty factor $\|\nabla_{\mathbf{f}} \mathcal{L}_{Bio.}\|$ (see Eq. 35) and the corresponding test performance. The results show that the training penalty factor $\|\nabla_{\mathbf{f}} \mathcal{L}_{Bio.}\|$ can be reduced when the potential test performance improves, so that the model can be trained at the convergent learning rate γ^* (see Eq. 35); and increases when the potential test performance decreases to jump out of the local optima and find the potential global optima; finally stops the model optimization after exploring a certain number of steps, and the converged model parameters are taken, which effectively enhances the generalization of the model.

To verify that GAFSE-HS and GAFSE-MO can achieve better generalization performance than AFSE [11], we compare four ligand-based virtual screening indexes of each method on benchmark datasets. As shown in Table II, when GAFSE-HS is compared with AFSE, the index $(EF_{10\%})$ of screening highly active molecules ($EF_{10\%}$) on all 33 tasks improved by an average of 1.29%; the index (r^2) for fitting the distribution of activity values increased by an average of 3.94%; the index (τ_B) for predicting the ranking of activity values increased by an average of 8.07%. These results show that the theoretically guaranteed learning rate definition (Eq. 35) of GAFSE-HS in this paper can generally improve the generalization performance of AFSE. Compared with GAFSE-HS, the average $EF_{10\%}$ and RMSE of GAFSE-MO are further improved by 0.32% and 0.73% on all 33 tasks, respectively. These results show that the reconstruction of the molecular graph by GAFSE-MO does not negatively affect the prediction of absolute activity values (RMSE) and the hit rate of highly active molecules ($EF_{10\%}$).

B. Generation of higher active drug molecules

Setup: To verify whether GAFSE can effectively generate matched high activity value drug molecules based on existing molecules, we screened out MMP-Cliffs (only one atom different, but their bioactivity values differ by more than 10 times), and the rest are used as the training set. We put molecules with lower activity values in MMP-Cliffs back into the training set to see if the molecules with higher activity values in MMP-Cliffs are included in our generated molecules.

Algorithm Review: This section is about GAFSE experiments in the molecule optimization (MO) stage of lead discovery, referred to as GAFSE-MO. The pipeline of GAFSE-MO is as follows: First, molecules are input into the molecular embedding model E in the form of graphs to obtain molecular embeddings **f**; then **f** is input to the downstream task model N to predict bioactivity values \hat{y} and obtain the adversarial disturbance vector **d** according to Eq. 12; next, **f** is input to the molecular reconstruction model G to reconstruct the initial graph features of input molecules $[\hat{a}_i, \hat{b}_{i,j}]$; meanwhile, $\mathbf{f} + \mathbf{d}$ is input into G to get the optimized molecular graph features $[\tilde{\mathbf{a}}_i, \tilde{\mathbf{b}}_{i,j}]$ and $[\tilde{\mathbf{a}}_i, \tilde{\mathbf{b}}_{i,j}]$ are optimized by Eq. 19 to update the overall model parameters simultaneously. In the testing phase of GAFSE-MO, the output \hat{y} is used to screen out highly active molecules (HS task), and the output $[\tilde{\mathbf{a}}_i, \tilde{\mathbf{b}}_{i,j}]$ is used to optimize molecules.

Results: Taking the orexin receptor O43614 in the UniProt database as an example, Figure 4 shows the location of GAFSE-generated molecules in the predicted structural feature-activity space. Results show that the predicted activities of most generated molecules are greatly increased, and their structural features are close to their original molecules, meeting the requirements of MMP-Cliffs. In Figure 4, according to Eq. 15, the projection of solid arrows on the x-y plane indicates GAFSE's d, which contains key information for generating MMP-Cliffs molecules. We queried the activity assays of orexin receptor O43614 and found that the true activities of four generated molecules (red stars in Figure 4) are much higher than that of their original molecules. Besides, the molecule optimization results of GAFSE-MO can provide chemists with more insight into molecule optimization by analyzing the changes in elements at different atomic positions between the generated and original molecules (dotted arrows in Figure 4).

In Table III, we present representative cases of highly active molecules generation by GAFSE-MO. In the table, "Anchors" represent low activity molecules in the training set, and "Generated molecules" represent high activity molecules generated by GAFSE-MO based on "Anchors". Results on multiple datasets show that the GAFSE-MO algorithm has a certain ability to generate highly active molecules in MMP-Cliffs. At the same time, we calculated various chemical properties of the generated molecules, including quantitative evaluation of drug-likeness (QED), synthesizable analysis (SA), and oil-water partition coefficient (LogP). Among them, the value of QED is between 0 and 1, and the larger the value, the higher the drug-likeness; the SA score is between 1 and 10, and the closer to 1, the easier synthesis; the drug is well absorbed when the logP is between 0 and 3, and smaller or larger values are not conducive to the absorption of the drug.

C. ADMET Property Prediction

Setup: To verify the ability of GAFSE to accurately predict molecular ADMET properties, we evaluate the prediction performance of GAFSE on the available ADMET benchmark datasets constructed in [14]. The experiments in this section use the same model settings as Section III-A, except $\lambda_1 = 0.08$ (Eq. 19) which is more suitable for multi-task learning. For a fair comparison with benchmark models of multi-task learning, we extend the multi-task learning scheme for GAFSE, that is, multi-tasks share model parameters other than the output

Targets	Anchors	Anchor Properties	Generated molecules	Generated Properties
		Activity: 8.6002 QED: 0.4766 SA: 2.7684 logP: 5.5007	HOS CID CID CID CID CID CID CID CID	Atom#16: S→O Activity: 9.6995 (++) QED: 0.5177 (+) SA: 2.5739 (+) logP: 5.0322 (+)
Human sphingosine 1-phosphate receptor (P21453)	HO30 $\xrightarrow{C2}$	Activity: 7.4225 QED: 0.5158 SA: 4.1048 logP: 5.4916		Atom#20: S→O Activity: 9.0000 (++) QED: 0.5638 (+) SA: 4.1124 logP: 5.0231 (+)
		Activity: 6.6576 QED: 0.6539 SA: 2.4926 logP: 4.5761		Atom#13: C→O Activity: 8.8861 (++) QED: 0.6575 SA: 2.5408 logP: 4.3699 (+)
		Activity: 7.5229 QED: 0.3473 SA: 2.6436 logP: 5.2999		Atom#20: S→O Activity: 8.6990 (++) QED: 0.3769 (+) SA: 2.6295 logP: 4.8314 (+)
Human orexin type 2 receptor (O43614)		Activity: 5.6882 QED: 0.7903 SA: 3.2084 logP: 3.4033	$ \begin{array}{c} $	Atom#13: N→O Activity: 7.2291 (++) QED: 0.7889 SA: 3.1571 logP: 3.4369
		Activity: 5.2358 QED: 0.7352 SA: 3.2157 logP: 3.6640		Atom#1: N→O Activity: 6.7747 (++) QED: 0.6690 (−) SA: 3.2724 logP: 4.0910 (−)
	$\begin{array}{c} c_{13} c_$	Activity: 7.6778 QED: 0.7370 SA: 2.2952 logP: 3.7714	$\begin{array}{c} c_{118} & c_{15} \\ c_{11} & c_{20} \\ c_{20} & c_{20} \\ c_{2$	Atom#13: O→S Activity: 9.3098 (++) QED: 0.7164 (-) SA: 2.4025 (-) logP: 4.1303 (-)
Human dopamine receptor (P14416)		Activity: 6.7696 QED: 0.8451 SA: 2.6875 logP: 4.5126		Atom#10: C→N Activity: 8.1675 (++) QED: 0.7950 (−) SA: 2.7957 (−) logP: 3.7864 (+)
	$\begin{array}{c} c_{14} \\ c_{13} \\ c_{12} \\ c_{2} \\ c_{17} \\ c_{16} \\ c_{17} \\ c_{16} \\ c_{16} \\ c_{17} \\ c_{16} \\ c_{18} \\ c_{19} \\ c_{19} \\ c_{19} \\ c_{10} \\ c_{10}$	Activity: 5.7545 QED: 0.8091 SA: 2.1075 logP: 4.0222	$\begin{array}{c} c_{14} \\ c_{13} \\ c_{14} \\ c_{14} \\ c_{15} \\ c_{15} \\ c_{15} \\ c_{16} \\ c_{16$	Atom#9: O->S Activity: 7.1337 (++) QED: 0.7847 (-) SA: 2.0823 logP: 4.4907 (-)

TABLE III Generation of higher active drug molecules by GAFSE-MO

layer. Among them, deeper neural networks with one more layer are used to learn multiple tasks, datasets with similar sample numbers are learned simultaneously, and the optimal classification threshold on the validation set is adopted. To reduce the computational cost, experiments in this section omit the molecule optimization part (Eq. 19), which is discussed in Section III-D.

Algorithm Review: This section is about GAFSE experiments in the molecular property prediction (MP) stage of lead discovery, referred to as GAFSE-MP. The difference between the algorithm of GAFSE-MP and GAFSE-HS in Section III-A is that the output prediction of the downstream task model N is molecular property values.

Results: As shown in Table IV, compared to ADMETlab 2.0, GAFSE-MP achieves performance improvements on most metrics across all 25 ADMET classification tasks. On average, the area under the precision-recall curve (AUC) of GAFSE-MP increased by 1.73%; the classification accuracy (ACC) increased by 2.40%; the quality of the binary classification (Matthews correlation coefficient, MCC) improved by 10.38%; and the specificity of binary classification is improved by 1.93%. Although the sensitivity of binary classification is

 TABLE IV

 Comparison of classification indexes on ADMET benchmark datasets [14]. Baseline results are taken from [14].

	AUC A		AC	C	MC	С	Specificity		Sensitivity		
Category	Model	ADMETlab2.0	GAFSE-MP	ADMETlab2.0	GAFSE-MP	ADMETlab2.0	GAFSE-MP	ADMETlab2.0	GAFSE-MP	ADMETlab2.0	GAFSE-MP
Absorption	Pgp-inhibitor	0.922	0.876	0.867	0.737	0.723	0.504	0.844	0.583	0.882	0.897
	Pgp-substrate	0.840	0.848	0.768	0.703	0.538	0.456	0.705	0.947	0.828	0.444
Distribution	BBB Penetration	0.908	0.805	0.862	0.768	0.718	0.521	0.824	0.796	0.891	0.727
Metabolism	CYP1A2 inhibitor	0.928	0.662	0.852	0.670	0.704	0.364	0.848	0.479	0.857	0.857
	CYP1A2 substrate	0.737	0.864	0.649	0.800	0.298	0.611	0.632	0.734	0.667	0.875
	CYP2C9 inhibitor	0.919	0.732	0.841	0.725	0.671	0.361	0.823	0.538	0.878	0.815
	CYP2C9 substrate	0.725	0.914	0.707	0.860	0.386	0.710	0.776	0.822	0.606	0.886
	CYP3A4 inhibitor	0.921	0.897	0.832	0.832	0.659	0.654	0.825	0.752	0.841	0.891
	CYP3A4 substrate	0.776	0.983	0.713	0.961	0.437	0.918	0.820	0.957	0.608	0.966
Toxicity	AMES Toxicity	0.902	0.872	0.807	0.906	0.606	0.283	0.732	0.925	0.865	0.480
	Eye Corrosion	0.983	0.851	0.957	0.849	0.908	0.499	0.965	0.881	0.944	0.678
	FDAMDD	0.804	0.945	0.736	0.897	0.471	0.647	0.734	0.916	0.737	0.791
	NR-AhR	0.943	0.918	0.862	0.887	0.573	0.538	0.858	0.912	0.896	0.701
	NR-AR-LBD	0.915	0.885	0.936	0.958	0.472	0.560	0.942	0.964	0.783	0.783
	NR-AR	0.886	0.832	0.890	0.909	0.348	0.499	0.896	0.956	0.731	0.515
	NR-Aromatase	0.852	0.907	0.849	0.930	0.264	0.454	0.859	0.933	0.615	0.842
	NR-ER-LBD	0.850	0.901	0.903	0.913	0.364	0.465	0.918	0.924	0.618	0.714
	NR-ER	0.771	0.878	0.815	0.832	0.320	0.350	0.845	0.841	0.567	0.717
	NR-PPAR-gamma	0.893	0.918	0.896	0.839	0.344	0.678	0.901	0.828	0.750	0.852
	Skin Sensitization	0.707	0.905	0.775	0.833	0.462	0.653	0.539	0.819	0.889	0.863
	SR-ARE	0.863	0.905	0.827	0.817	0.469	0.624	0.850	0.830	0.701	0.798
	SR-ATAD5	0.874	0.967	0.919	0.909	0.361	0.819	0.929	0.905	0.640	0.914
	SR-HSE	0.907	0.929	0.868	0.985	0.393	0.754	0.875	0.999	0.750	0.615
	SR-MMP	0.927	0.931	0.897	0.886	0.660	0.399	0.908	0.892	0.835	0.758
	SR-p53	0.881	0.866	0.841	0.954	0.365	0.503	0.849	0.964	0.723	0.680
	Average	0.865	0.880	0.835	0.855	0.501	0.553	0.828	0.844	0.764	0.762

reduced by 0.26% on average, these results can also show that the GAFSE framework can be used for classification and incorporate multi-task learning strategy, exhibiting its high scalability and potentiality to be studied as an open unified framework.

D. ADMET Property Optimization

Setup: To verify whether GAFSE can effectively optimize ADMET properties of existing molecules, we screened out MMP-Cliffs (elements with only one atom are not the same, but the molecule changes from highly toxic to non-toxic, or from no specific properties to specific properties) in typical ADMET datasets in Table IV, and the rest are used as the training set. Then, we put the MMP-Cliffs molecules with strong toxicity or no specific properties back into the training set, and observe whether the MMP-Cliffs molecules generated by GAFSE have non-toxic or specific properties. The experiments in this section use the same model settings as Section III-B.

Algorithm Review: This section is about the GAFSE experiments in the molecule optimization (MO) stage of lead discovery, namely GAFSE-MO. The difference between GAFSE-MO in this section and Section III-A is that the downstream task model N predicts molecular property values, and the molecular reconstruction model G optimizes molecular properties.

Result: In Table V, we present representative GAFSE-MO optimization results from highly toxic molecules to nontoxic MMP-Cliffs molecules. In the table, "Anchors" represent the highly toxic molecules in the training set, and "Generated molecules" represent the non-toxic molecules generated by GAFSE-MO based on "Anchors". Results on multiple datasets show that GAFSE-MO has a certain ability to optimize molecular toxicity. At the same time, we calculated various chemical properties of the resulting molecules, including quantitative evaluation of drug-likeness (QED), synthesizable analysis (SA), and oil-water partition coefficient (LogP). Among them, the value of QED is between 0 and 1, and the larger the value, the higher the drug-likeness; the SA is between 1 and 10, and the closer to 1, the easier synthesis; drugs with a logP between 0 and 3 are better absorbed, and smaller or larger values are less favorable for drug absorption. From Table V, it can be seen that most of the molecules have improved druglike properties, higher synthesis feasibility, and better drug absorption after GAFSE toxicity optimization.

Additionally, Table VI shows some examples of GAFSE-MO optimizing non-inhibitor molecules to inhibitor MMP-Cliffs molecules. In the table, "Anchors" refers to the non-inhibitor molecules in the training set, and "Generated molecules" refers to the inhibitor molecules generated by GAFSE-MO based on "Anchors". We also calculated the QED, SA, and LogP metrics for all molecules. It can be seen from the results that, compared with non-inhibitor molecules, GAFSE-optimized inhibitor molecules can become more druglike, synthesizable, or absorbable.

E. Exploring molecular generation on COVID-19

Setup: To explore the properties of GAFSE-optimized molecules in COVID-19-related databases, we used the AID1706 bioassay data in the PubChem database ¹, which is a high-throughput screening assay to identify inhibitors of the SARS coronavirus 3CLPro. For a fair comparison, we adopted the same experimental setup as [15], that is, using 444 molecules with an activity score higher than 15 and less than 100 in a total of 290K molecules, 100 molecules were randomly selected as the test set, and the rest were used as the training set.

¹https://pubchem.ncbi.nlm.nih.gov/bioassay/1706

Targets	Anchors	Anchor Properties	Generated molecules	Generated Properties
	C:7C:6 C:11C:12 C:8 C:9C:10 C:3C:2	Toxicity: High QED: 0.6155 SA: 1.2681 logP: 3.8570	C:7C:6 C:11C:12 C:8 C:5C:4 C:1O:0H C:9C:10 C:3C:2	Atom#0: N→O Toxicity: Non-Toxic QED: 0.6969 (+) SA: 1.2254 logP: 3.0592 (+)
NR-AhR Toxicity	C:0 C:3 C:4 C:5 N:6H ₂ C:7	Toxicity: High QED: 0.5630 SA: 1.4461 logP: 2.4220	$\begin{array}{c} C:0 \\ C:3 \\ C:5 \\ C:5 \\ C:8 \\ C:7 \end{array}$	Atom#6: N→C Toxicity: Non-Toxic QED: 0.5532 SA: 1.0100 (+) logP: 2.0036
	C:4 C:4 C:5 C:6 C:6 C:7H C:3 C:2 C:0.7H	Toxicity: High QED: 0.3762 SA: 1.8671 logP: 1.4854	C:4 C:5 C:6 C:7 C:7 C:7 C:7 C:7 C:7 C:7 C:7	Atom#7: O→C Toxicity: Non-Toxic QED: 0.5359 (++) SA: 1.4050 (+) logP: 1.7006
	C:0 C:1 C:3 C:5	Toxicity: High QED: 0.5285 SA: 2.7983 logP: -0.0712	C:0 C:1 C:3 C:5	Atom#4: N→C Toxicity: Non-Toxic QED: 0.5586 (+) SA: 2.6752 logP: 1.4133 (++)
NR-ER Toxicity	C:6 N:5-C:4 C:7 C:3-C:2	Toxicity: High QED: 0.5694 SA: 1.3958 logP: 2.0610	C:6 C:8 C:9 C:5 C:4 C:1 C:0 C:7 C:3 C:2	Atom#5: N→C Toxicity: Non-Toxic QED: 0.5533 SA: 1.2512 (+) logP: 3.1184 (-)
	0:4 C:3 HO:5 O:2H	Toxicity: High QED: 0.4539 SA: 2.3257 logP: -0.5482	H0:5 C:3-C:1 O:4 N:2H ₂	Atom#2: O→N Toxicity: Non-Toxic QED: 0.4514 SA: 2.3196 logP: -0.5818
	C:0 C:1 C:3 O:5H	Toxicity: High QED: 0.3211 SA: 2.3758 logP: 1.2761	C:0 C:1 C:3 O:5H	Atom#4: N→C Toxicity: Non-Toxic QED: 0.5133 (++) SA: 1.5665 (+) logP: 1.1689
AMES Toxicity	C:0-C:1 C:8=C:6 O:7H	Toxicity: High QED: 0.4030 SA: 1.8514 logP: 1.2828	C:0-C:3 C:0-C:3 C:8=C:6 O:7H	Atom#5: N→C Toxicity: Non-Toxic QED: 0.5577 (++) SA: 1.5860 (+) logP: 2.0090
		Toxicity: High QED: 0.4312 SA: 2.3371 logP: 3.1547	C1 - C0 C1 - C1 C2 - C0 C1 - C1 C1	Atom#4: O→S Toxicity: Non-Toxic QED: 0.4360 SA: 2.5031 logP: 3.2711

 TABLE V

 Generation of matched non-toxic molecules from toxic molecules by GAFSE-MO.

Algorithm Review: This section is about GAFSE experiments in the molecule optimization (MO) stage of lead discovery, which is consistent with the GAFSE-MO algorithm in Section III-B.

Evaluation metrics: To comprehensively evaluate the performance of molecule generation, we use 4 commonly used metrics to test the model, namely reconstruction rate, validation rate, unique rate, and novelty rate. Among them, the reconstruction rate refers to the proportion of successfully reconstructed molecules in the test sets; the validation rate refers to the proportion of the molecules that meet the chemical specifications in the test sets; the unique rate refers to the proportion of unique molecules generated in the test set; the novelty rate refers to the proportion of generated molecules that differ from those in the test set.

Results: In Table VII, we compare the performance of various types of molecular generative models, including (1) five variational autoencoder (VAE)-based models: junc-

tion tree (JT)-VAE [23], Character-VAE [24], Grammar-VAE [25], syntax-directed (SD)-VAE [26] and GraphVAE [27]; (2) an atom-by-atom AR long short-term memory (LSTM) model: AR-LSTM [28]; (3) two flow-base models: GraphNVP [29] and graph residual flow (GRF) [30]; (4) a geometrybased constrained VAE model: GEOM-CVAE [15] and (5) graph adversarial autoencoder (GAAE)-based model: GAFSE-MO. Results in Table VII show that GAFSE-MO achieves 100% in validation rate, unique rate, and novelty rate, and achieves a high reconstruction rate of 94%, which significantly outperforms the current state-of-the-art molecular generation methods in average performance. The five molecules with the highest QED scores generated by GAFSE-MO and other methods are reported in Table VIII. It can be seen that the QED of GAFSE-generated molecules can reach higher. We present the SIMILES, molecular graphs, and chemical properties of these Top-5 molecules in Table IX. Results show that the highly drug-like molecules generated by GFASE-MO based

Targets	Anchors	Anchor Properties	Generated molecules	Generated Properties
		Is Inhibitor: No QED: 0.7507 SA: 1.9675 logP: 2.3313		Atom#3: O→C Is Inhibitor: Yes QED: 0.7430 SA: 1.8747 IogP: 2.4881
CYP1A2 Inhibitor –		Is Inhibitor: No QED: 0.9151 SA: 2.6567 logP: 1.8996		Atom#20: N→C Is Inhibitor: Yes QED: 0.9228 SA: 2.4424 (+) logP: 2.5046
CYP2C9 Inhibitor		Is Inhibitor: No QED: 0.5026 SA: 2.5278 logP: 2.9390		Atom#18: $O \rightarrow N$ Is Inhibitor: Yes QED: 0.5447 (+) SA: 2.6015 logP: 2.5120 (+)
CYP2C9 Inhibitor –		Is Inhibitor: No QED: 0.4653 SA: 2.4246 logP: 2.8861		Atom#27: O→N Is Inhibitor: Yes QED: 0.5041 (+) SA: 2.4922 logP: 2.4591
CVD2A4 Lebilitar	c_{1}^{44} c_{2}^{44} c_{2}^{46} c_{13}^{46} c_{13}^{46} c_{13}^{46} c_{13}^{46} c_{13}^{46} c_{13}^{46} c_{14}^{46} $c_{$	Is Inhibitor: No QED: 0.8458 SA: 2.8367 logP: 2.9994		Atom#19: N→C Is Inhibitor: Yes QED: 0.8412 SA: 2.6357 (+) logP: 3.6044 (-)
CTP3A4 Inhibitor -		Is Inhibitor: No QED: 0.8467 SA: 3.2989 logP: 1.5469		Atom#18: $N \rightarrow C$ Is Inhibitor: Yes QED: 0.8542 SA: 3.1168 logP: 2.1519

 TABLE VI

 Generation of matched inhibitor molecules from non-inhibitor molecules by GAFSE-MO.

 TABLE VII

 Comparison of molecule generation on AID1706. Baseline results are taken from [15].

Model type	Model	Rec.	Val.	Uni.	Nov.	Avg.
	JT-VAE	76.7%	100%	-	-	88.35%
	Character-VAE	44.6%	0.7%	-	-	22.65%
VAE-based	Grammar-VAE	53.7%	7.2%	-	-	30.45%
	SD-VAE	76.2%	43.5%	-	-	59.85%
	GraphVAE	-	13.5%	-	-	13.5%
AR-based	AR-LSTM	-	89.2%	-	-	89.2%
Flow based	GraphNVP	100%	42.6%	94.8%	100%	84.35%
Flow-based	GRF	100%	73.4%	53.7%	100%	81.78%
Geometry-based	GEOM-CVAE	100%	81.8%	100%	94.11%	93.98%
GAAE-based	GAFSE-MO	94%	100%	100%	100%	98.5%

TABLE VIII The comparison on the Top-5 QED scores of generated novel molecules. Baseline results are taken from [15].

Model	1st	2nd	3rd	4th	5th
JT-VAE	0.925	0.911	0.910	-	-
GEOM-CVAE	0.9442	0.9425	0.9120	0.9111	0.9089
GAFSE-MO	0.9461	0.9448	0.9363	0.9351	0.9241

on the active molecules of COVID-19 are highly synthesizable and have good absorbability.

TABLE IX Generated novel molecules with the Top-5 QED scores by GAFSE-MO.

Rank	Canonical SMILES	Molecular graphs	Chemical Properties
1st	O=C(Cc1cccnc1) Nc1ccc(F)c(Br)c1		QED: 0.9461 (++) SA: 1.8498 (++) logP: 3.1644
2rd	Cc1ccc(NC(=O) Cc2cccnc2)cc1Br	Q40	QED: 0.9448 (++) SA: 1.8236 (++) logP: 3.3337
3rd	Cc1ccc(F)cc1OC (C)C(=O)Nc1nccs1	que	QED: 0.9363 (++) SA: 2.5038 (+) logP: 2.9966 (+)
4th	O=C(Cc1cccnc1) Nc1ccc(Cl)c(Br)c1		QED: 0.9351 (++) SA: 1.8990 (++) logP: 3.6787
5th	Cc1ccc(Br)cc1OC (C)C(=O)Nc1nccs1	q.p	QED: 0.9241 (++) SA: 2.5552 (+) logP: 3.6200

IV. DISCUSSION

A. Urgent Need for A One-Stop Framework across Lead Discover Stages

To underscore the urgent need for a one-stop framework across lead discovery stages, we evaluate the compatibility of discrete models in their lead discovery stages (see Table X),

HERENCE EVALU	JATION OF MACHINE	E LEARNING MODELS	TABLE X 5 ACROSS LEAD DISCOVERY STAGES. N	IODELS ARE PAIRED AS COMPATIBLE AS PC	SSIBLE.
HS models	MP models	MO models	Compatibility	Incompatibility	Score
SVM, LR, k-NN, SEA 31], WDL-RF [7]	RF [32], k-NN [33], SVM [34], SwissADME [35], CNN [36], ADMETIab [37], admetSAR 2.0	All mentioned MO models	None	MP models' Encoder: input molecular descriptors or images (CNN), no graph embedding output (-2);	<-2

Encoder: output graph embedding

vectors (+1); Training Strategy:

end-to-end (+1)

Encoder: input one molecular

graph, output graph embedding

vectors (+1)

Encoder: input one molecular

graph, output graph embedding

vectors (+1); Training Strategy:

end-to-end (+1)

Encoder: input one molecular

graph, output graph embedding

vectors (+1); Training Strategy:

end-to-end (+1)

Training Strategy: end-to-end

(+1); Evaluation Data: assayed

molecular properties through

biological wet experiments (+1) Encoder: input one molecular graph, output graph embedding vectors (+1); Training: end-to-end

(+1); Evaluation Data: assayed

molecular activities and properties through biological wet experiments (+2)

including hit screening (HS), molecular property prediction
(MP) and molecule optimization (MO) models. When we
try to unify these discrete models, we find that they suffer
from various types of incompatibilities. For example, when
the encoder is shared, the input and output are different,
which leads to the failure of part of the encoder at differ-
ent stages; different training strategies increase the difficulty
of simultaneous convergence of the models across different
stages; simulated or predicted molecular property values,
rather than biological wet experimental values, are used to
train and evaluate models, which hinders the widespread use

S k-l

DGL-based

models

DGL-based

models

DGL-based

models: GCNs

[42], GATs

[43], GINs

[44], Neural

FP [45], Weave

[46], MPNNs

[47], Attentive

FP [16],

RealVS [10].

AFSE [11]

DGL-based

models

DGL-based

models

[38]

MTNN-GCN

[39],

ADMETlab2.0

[14]

MTNN-GCN

[39],

ADMETlab2.0

[14]

MTNN-GCN

[39], GNN

models [5],

ADMETlab2.0

[14]

MTNN-GCN

[39], GNN

models [5],

ADMETlab2.0

[14]

MTNN-GCN

[39],

ADMETlab2.0

[14]

GAFSE

DeltaDelta [40]

MolEvol [41]

CORE [48],

α-MOP [49],

Modof [50],

MOLER [51],

SPEAR [52],

SCVAE [53]

UGMMT [54]

QMO [55]

[31]

of incorporated models. Therefore, as a one-stop framework, GAFSE effectively unifies all stages of lead discovery and is an important advance in improving the efficiency of drug developers and drug discovery success rates.

-2

-1

 $-1 \sim 0$

0

+1

+4

DeltaDelta's Encoder: input paired protein and ligand voxelization,

extra output protein embedding

vectors (-3); DeltaDelta's

Evaluation Data: simulated or

predicted values rather than experimentally measured (-1)

MolEvol's Encoder: extra input a

paired molecular graph (-1);

MolEvol's Training Strategy: two

stages (-1);

CORE, α -MOP, Modof, MOLER,

SPEAR, and SCVAE's Encoder:

extra input a paired moelcular

graph and their junction trees,

extra output junction tree

embedding vectors (-2); CORE,

 α -MOP, Modof, SPEAR, and

MOLER's Evaluation Data:

simulated or predicted values

rather than experimentally

measured (-1) UGMMT's Encoder: extra input a

paired molecular graph (-1);

UGMMT's Evaluation Data:

simulated or predicted values

rather than experimentally

measured (-1)

QMO's Encoder: input molecular

sequences (-1), output sequential

embeddings

None

The following is an introduction to the models included in Table X. HS models can be divided into two categories: deep graph learning (DGL)-based and non-DGL-based. DGL-based models include: graph convolutional networks (GCNs) [42], graph attention networks (GATs) [43], graph isomorphism networks (GINs) [44] pre-trained with supervised learning and context prediction [56], neural fingerprint (Neural FP) [45],

Weave [46], message passing neural networks (MPNNs) [47], attentive fingerprint (Attentive FP) [16], real virtual screening (RealVS) [10], and adversarial feature subspace enhancement (AFSE) [11]; Non-DGL-based models include: support vector machines (SVM), logistic regression (LR), k-nearest neighbor (k-NN), similarity ensemble approaches (SEA) [31], weighted deep learning combined with random forest (WDL-RF) [7]; MP prediction models include: random forest (RF) [32], knearest neighbor (k-NN) [33], support vector machines (SVM) [34], SwissADME [35], ADMETlab [37], admetSAR 2.0 [38], fully-connected multitask networks and graph convolutional multitask networks (MTNN-GCN) [39], convolutional neural network (CNN) [36], graph neural network models (GNN models) reviewed in [5], and ADMETlab 2.0 [14]; MO models include: automatic molecule optimization using copy & refine strategy (CORE) [48], molecule optimization with α -divergence (α -MOP) [49], DeltaDelta neural networks for lead optimization of small molecule potency (DeltaDelta) [40], molecule optimization by explainable evolution (MolEvol) [41], a deep generative model for molecule optimization via one fragment modification (Modof) [50], molecule-level reward functions (MOLER) [51], unpaired Generative Moleculeto-Molecule Translation for Lead Optimization (UGMMT) [54], self-supervised post-training enhancer for molecule optimization (SPEAR) [52], structure-aware conditional variational auto-encoder (SCVAE) [53], and a generic query-based molecule optimization (QMO) [55].)

B. Absence of novel MMP-Cliffs generation studies

As the most basic and most valuable molecule optimization method[57], MMP-Cliffs usually contains high structureactivity relationship (SAR) information [58], [59], which inspires pharmacists to discover and design high-efficiency molecules [60]. MMP-Cliffs are widely used in medicinal chemistry to study changes in compound properties, including biological activity, toxicity, environmental hazards, etc. [61]. Existing MMP-Cliffs analysis methods mainly answer the following three questions: how to identify MMP-Cliffs[57], [62], [63], [64], [65], [66], how to predict MMP-Cliffs[60], [67], [68], [69], [70], [71], and how to optimize molecules according to MMP-Cliffs [59], [72], [73]. However, these methods are still limited to MMP-Cliffs in existing molecular libraries, and cannot generate novel MMP-Cliffs to open up the idea of molecule optimization. Therefore, in this paper, GAFSE generates novel MMP-Cliffs by modifying elements on one single atomic site (Figure 2b), which achieves a substantial optimization of molecular properties and provides an important reference for drug discovery.

C. Openness Check: Incorporating Multi-Task Learning into the GAFSE Framework

In the molecular property prediction experiments (Section III-C), we found that optimizing more tasks simultaneously improves the overall performance of GAFSE-MP. Due to the confidentiality ² of the data, we only obtained part of the

dataset in ADMETIab 2.0 [14]. Nevertheless, GAFSE-MP still achieves competitive overall performances incorporating multi-task learning (see Table IV). These results indicate that the GAFSE framework is open. Researchers can adapt GAFSE to custom scenarios by replacing or adding advanced methods to further improve the efficiency and success rate of drug discovery.

V. CONCLUSION

GAFSE unifies the discovery of lead compounds under an open learning framework, develops algorithms based on their consistency and uniqueness, and solves unique problems in each step. Extensive experimental results demonstrate that GAFSE can efficiently generate novel and highly active MMP-Cliffs molecules, and its performance in predicting activity values and ADMET properties is as good as the state-of-theart methods. Nevertheless, there are remains many unresolved problems in lead compound discovery. Therefore, GAFSE can be extended as an open framework with open source code, convenient interfaces, and documentation for community participation and subsequent development.

In the future, we will use a large molecular database to pre-train models in the GAFSE framework, so that they can be adapted to various downstream tasks. In addition, the definitions of MMP-Cliffs are varied, and so, we will try to transform a substructure to build multi-objective optimization models of MMP-Cliffs.

DATA AVAILABILITY

All datasets used in this paper can be downloaded from our GitHub repositories ³. Among them, ADMET's datasets were downloaded from ADMETlab 2.0 ⁴.

CODE AVAILABILITY

Code developed in this paper can be downloaded from our GitHub repositories ⁵.

ACKNOWLEDGMENTS

This work was supported in part by the National Natural Science Foundation of China (62071242, 61571233, 61901229, 61872198, and 61971216); the Natural Science Foundation of Jiangsu Province (BK20201378). Other contributors to this work: Li Hoi Yeung, Adams Wai Kin Kong, Yanxiang Zhu (Support).

REFERENCES

- S.-s. Ou-Yang, J.-y. Lu, X.-q. Kong, Z.-j. Liang, C. Luo, and H. Jiang, "Computational drug discovery," *Acta Pharmacologica Sinica*, vol. 33, no. 9, pp. 1131–1140, 2012.
- [2] B. Shaker, S. Ahmad, J. Lee, C. Jung, and D. Na, "In silico methods and tools for drug discovery," *Computers in biology and medicine*, vol. 137, p. 104851, 2021.
- [3] M. Bahi and M. Batouche, "Deep learning for ligand-based virtual screening in drug discovery," in 2018 3rd International Conference on Pattern Analysis and Intelligent Systems (PAIS). IEEE, 2018, pp. 1–5.

³https://github.com/Yueming-Yin/GAFSE/tree/main/Data

⁴https://admetmesh.scbdd.com/resources/DA

⁵https://github.com/Yueming-Yin/GAFSE

- [4] R. Ramakrishnan, P. O. Dral, M. Rupp, and O. A. Von Lilienfeld, "Quantum chemistry structures and properties of 134 kilo molecules," *Scientific data*, vol. 1, no. 1, pp. 1–7, 2014.
- [5] O. Wieder, S. Kohlbacher, M. Kuenemann, A. Garon, P. Ducrot, T. Seidel, and T. Langer, "A compact review of molecular property prediction with graph neural networks," *Drug Discovery Today: Technologies*, vol. 37, pp. 1–12, 2020.
- [6] L. Xiao and J. Pennington, "Synergy and symmetry in deep learning: Interactions between the data, model, and inference algorithm," arXiv preprint arXiv:2207.04612, 2022.
- [7] J. Wu, Q. Zhang, W. Wu, T. Pang, H. Hu, W. K. Chan, X. Ke, and Y. Zhang, "Wdl-rf: predicting bioactivities of ligand molecules acting with g protein-coupled receptors by combining weighted deep learning and random forest," *Bioinformatics*, vol. 34, no. 13, pp. 2271–2282, 2018.
- [8] J. Wu, B. Liu, W. K. Chan, W. Wu, T. Pang, H. Hu, S. Yan, X. Ke, and Y. Zhang, "Precise modelling and interpretation of bioactivities of ligands targeting g protein-coupled receptors," *Bioinformatics*, vol. 35, no. 14, pp. i324–i332, 2019.
- [9] J. Wu, Y. Sun, W. K. Chan, Y. Zhu, W. Zhu, W. Huang, H. Hu, S. Yan, T. Pang, and X. Ke, "Homologous g protein-coupled receptors boost the modeling and interpretation of bioactivities of ligand molecules," *Journal of chemical information and modeling*, vol. 60, no. 3, pp. 1865– 1875, 2020.
- [10] Y. Yin, H. Hu, Z. Yang, H. Xu, and J. Wu, "Realvs: Toward enhancing the precision of top hits in ligand-based virtual screening of drug leads from large compound databases," *Journal of Chemical Information and Modeling*, vol. 61, no. 10, pp. 4924–4939, 2021.
- [11] Y. Yin, H. Hu, Z. Yang, F. Jiang, Y. Huang, and J. Wu, "Afse: towards improving model generalization of deep graph learning of ligand bioactivities targeting gpcr proteins," *Briefings in Bioinformatics*, vol. 23, no. 3, p. bbac077, 2022.
- [12] T. Le, V. C. Epa, F. R. Burden, and D. A. Winkler, "Quantitative structure-property relationship modeling of diverse materials properties," *Chemical reviews*, vol. 112, no. 5, pp. 2889–2919, 2012.
- [13] M. Cruz-Monteagudo, J. L. Medina-Franco, Y. Perez-Castillo, O. Nicolotti, M. N. D. Cordeiro, and F. Borges, "Activity cliffs in drug discovery: Dr jekyll or mr hyde?" *Drug Discovery Today*, vol. 19, no. 8, pp. 1069–1080, 2014.
- [14] G. Xiong, Z. Wu, J. Yi, L. Fu, Z. Yang, C. Hsieh, M. Yin, X. Zeng, C. Wu, A. Lu *et al.*, "Admetlab 2.0: an integrated online platform for accurate and comprehensive predictions of admet properties," *Nucleic Acids Research*, vol. 49, no. W1, pp. W5–W14, 2021.
- [15] C. Li, J. Yao, W. Wei, Z. Niu, X. Zeng, J. Li, and J. Wang, "Geometrybased molecular generation with deep constrained variational autoencoder," *IEEE Transactions on Neural Networks and Learning Systems*, 2022.
- [16] Z. Xiong, D. Wang, X. Liu, F. Zhong, X. Wan, X. Li, Z. Li, X. Luo, K. Chen, and H. Jiang, "Pushing the boundaries of molecular representation for drug discovery with the graph attention mechanism," *Journal* of medicinal chemistry, vol. 63, no. 16, pp. 8749–8760, 2019.
- [17] A. Vaswani, N. Shazeer, N. Parmar, J. Uszkoreit, L. Jones, A. N. Gomez, L. Kaiser, and I. Polosukhin, "Attention is all you need," *arXiv preprint arXiv*:1706.03762, 2017.
- [18] Y. Yin, Z. Yang, H. Hu, and X. Wu, "Metric-learning-assisted domain adaptation," *Neurocomputing*, vol. 454, pp. 268–279, 2021.
- [19] Y. Yin, Z. Yang, X. Wu, and H. Hu, "Pseudo-margin-based universal domain adaptation," *Knowledge-Based Systems*, vol. 229, p. 107315, 2021.
- [20] Y. Yin, Z. Yang, H. Hu, and X. Wu, "Universal multi-source domain adaptation for image classification," *Pattern Recognition*, vol. 121, p. 108238, 2022.
- [21] M. Khamsi and W. Kirk, An Introduction to Metric Spaces and Fixed Point Theory, ser. Pure and Applied Mathematics: A Wiley Series of Texts, Monographs and Tracts. Wiley, 2001.
- [22] K. Eriksson, D. Estep, and C. Johnson, "Lipschitz continuity," in Applied Mathematics: Body and Soul. Springer, 2004, pp. 149–164.
- [23] W. Jin, R. Barzilay, and T. Jaakkola, "Junction tree variational autoencoder for molecular graph generation," in *International conference on machine learning*. PMLR, 2018, pp. 2323–2332.
- [24] R. Gómez-Bombarelli, J. N. Wei, D. Duvenaud, J. M. Hernández-Lobato, B. Sánchez-Lengeling, D. Sheberla, J. Aguilera-Iparraguirre, T. D. Hirzel, R. P. Adams, and A. Aspuru-Guzik, "Automatic chemical design using a data-driven continuous representation of molecules," ACS central science, vol. 4, no. 2, pp. 268–276, 2018.

- [25] M. J. Kusner, B. Paige, and J. M. Hernández-Lobato, "Grammar variational autoencoder," in *International conference on machine learning*. PMLR, 2017, pp. 1945–1954.
- [26] H. Dai, Y. Tian, B. Dai, S. Skiena, and L. Song, "Syntax-directed variational autoencoder for structured data," in *International Conference* on *Learning Representations*, 2018.
- [27] M. Simonovsky and N. Komodakis, "Graphvae: Towards generation of small graphs using variational autoencoders," in *International conference* on artificial neural networks. Springer, 2018, pp. 412–422.
- [28] Y. Li, O. Vinyals, C. Dyer, R. Pascanu, and P. Battaglia, "Learning deep generative models of graphs," arXiv preprint arXiv:1803.03324, 2018.
- [29] K. Madhawa, K. Ishiguro, K. Nakago, and M. Abe, "Graphnvp: An invertible flow model for generating molecular graphs," arXiv preprint arXiv:1905.11600, 2019.
- [30] S. Honda, H. Akita, K. Ishiguro, T. Nakanishi, and K. Oono, "Graph residual flow for molecular graph generation," *arXiv preprint* arXiv:1909.13521, 2019.
- [31] T. Unterthiner, A. Mayr, G. Klambauer, M. Steijaert, J. K. Wegner, H. Ceulemans, and S. Hochreiter, "Deep learning as an opportunity in virtual screening," in *Proceedings of the deep learning workshop at NIPS*, vol. 27, 2014, pp. 1–9.
- [32] V. Svetnik, A. Liaw, C. Tong, J. C. Culberson, R. P. Sheridan, and B. P. Feuston, "Random forest: a classification and regression tool for compound classification and qsar modeling," *Journal of chemical information and computer sciences*, vol. 43, no. 6, pp. 1947–1958, 2003.
- [33] Y. Sakiyama, "The use of machine learning and nonlinear statistical tools for adme prediction," *Expert opinion on drug metabolism & toxicology*, vol. 5, no. 2, pp. 149–169, 2009.
- [34] K. Heikamp and J. Bajorath, "Support vector machines for drug discovery," *Expert opinion on drug discovery*, vol. 9, no. 1, pp. 93–104, 2014.
- [35] A. Daina, O. Michielin, and V. Zoete, "Swissadme: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules," *Scientific reports*, vol. 7, no. 1, pp. 1–13, 2017.
- [36] T. Shi, Y. Yang, S. Huang, L. Chen, Z. Kuang, Y. Heng, and H. Mei, "Molecular image-based convolutional neural network for the prediction of admet properties," *Chemometrics and Intelligent Laboratory Systems*, vol. 194, p. 103853, 2019.
- [37] J. Dong, N.-N. Wang, Z.-J. Yao, L. Zhang, Y. Cheng, D. Ouyang, A.-P. Lu, and D.-S. Cao, "Admetlab: a platform for systematic admet evaluation based on a comprehensively collected admet database," *Journal of cheminformatics*, vol. 10, no. 1, pp. 1–11, 2018.
- [38] H. Yang, C. Lou, L. Sun, J. Li, Y. Cai, Z. Wang, W. Li, G. Liu, and Y. Tang, "admetsar 2.0: web-service for prediction and optimization of chemical admet properties," *Bioinformatics*, vol. 35, no. 6, pp. 1067– 1069, 2019.
- [39] F. Montanari, L. Kuhnke, A. Ter Laak, and D.-A. Clevert, "Modeling physico-chemical admet endpoints with multitask graph convolutional networks," *Molecules*, vol. 25, no. 1, p. 44, 2019.
- [40] J. Jiménez-Luna, L. Pérez-Benito, G. Martinez-Rosell, S. Sciabola, R. Torella, G. Tresadern, and G. De Fabritiis, "Deltadelta neural networks for lead optimization of small molecule potency," *Chemical science*, vol. 10, no. 47, pp. 10911–10918, 2019.
- [41] B. Chen, T. Wang, C. Li, H. Dai, and L. Song, "Molecule optimization by explainable evolution," in *International Conference on Learning Representation (ICLR)*, 2021.
- [42] T. N. Kipf and M. Welling, "Semi-supervised classification with graph convolutional networks," arXiv preprint arXiv:1609.02907, 2016.
- [43] P. Veličković, G. Cucurull, A. Casanova, A. Romero, P. Lio, and Y. Bengio, "Graph attention networks," arXiv preprint arXiv:1710.10903, 2017.
- [44] K. Xu, W. Hu, J. Leskovec, and S. Jegelka, "How powerful are graph neural networks?" arXiv preprint arXiv:1810.00826, 2018.
- [45] D. K. Duvenaud, D. Maclaurin, J. Iparraguirre, R. Bombarell, T. Hirzel, A. Aspuru-Guzik, and R. P. Adams, "Convolutional networks on graphs for learning molecular fingerprints," *Advances in Neural Information Processing Systems*, vol. 28, pp. 2224–2232, 2015.
- [46] S. Kearnes, K. McCloskey, M. Berndl, V. Pande, and P. Riley, "Molecular graph convolutions: moving beyond fingerprints," *Journal* of computer-aided molecular design, vol. 30, no. 8, pp. 595–608, 2016.
- [47] J. Gilmer, S. S. Schoenholz, P. F. Riley, O. Vinyals, and G. E. Dahl, "Neural message passing for quantum chemistry," in *International Conference on Machine Learning*. PMLR, 2017, pp. 1263–1272.
- [48] T. Fu, C. Xiao, and J. Sun, "Core: Automatic molecule optimization using copy & refine strategy," in *Proceedings of the AAAI Conference* on Artificial Intelligence, vol. 34, no. 01, 2020, pp. 638–645.

- [49] T. Fu, C. Xiao, L. M. Glass, and J. Sun, "α-mop: Molecule optimization with α-divergence," in 2020 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2020, pp. 240–244.
- [50] Z. Chen, M. R. Min, S. Parthasarathy, and X. Ning, "A deep generative model for molecule optimization via one fragment modification," *Nature Machine Intelligence*, vol. 3, no. 12, pp. 1040–1049, 2021.
- [51] T. Fu, C. Xiao, L. Glass, and J. Sun, "Moler: Incorporate molecule-level reward to enhance deep generative model for molecule optimization," *IEEE Transactions on Knowledge and Data Engineering*, 2021.
- [52] T. Fu, C. Xiao, K. Huang, L. M. Glass, and J. Sun, "Spear: selfsupervised post-training enhancer for molecule optimization," in *Proceedings of the 12th ACM Conference on Bioinformatics, Computational Biology, and Health Informatics*, 2021, pp. 1–10.
- [53] J. Yu, T. Xu, Y. Rong, J. Huang, and R. He, "Structure-aware conditional variational auto-encoder for constrained molecule optimization," *Pattern Recognition*, vol. 126, p. 108581, 2022.
- [54] G. Barshatski and K. Radinsky, "Unpaired generative molecule-tomolecule translation for lead optimization," in *Proceedings of the 27th* ACM SIGKDD Conference on Knowledge Discovery & Data Mining, 2021, pp. 2554–2564.
- [55] S. C. Hoffman, V. Chenthamarakshan, K. Wadhawan, P.-Y. Chen, and P. Das, "Optimizing molecules using efficient queries from property evaluations," *Nature Machine Intelligence*, vol. 4, no. 1, pp. 21–31, 2022.
- [56] W. Hu, B. Liu, J. Gomes, M. Zitnik, P. Liang, V. Pande, and J. Leskovec, "Strategies for pre-training graph neural networks," *arXiv preprint* arXiv:1905.12265, 2019.
- [57] J. Bajorath, "Representation and identification of activity cliffs," *Expert Opinion on Drug Discovery*, vol. 12, no. 9, pp. 879–883, 2017.
- [58] D. Dimova and J. Bajorath, "Extraction of sar information from activity cliff clusters via matching molecular series," *European Journal of Medicinal Chemistry*, vol. 87, pp. 454–460, 2014.
- [59] S. Turk, B. Merget, F. Rippmann, and S. Fulle, "Coupling matched molecular pairs with machine learning for virtual compound optimization," *Journal of Chemical Information and Modeling*, vol. 57, no. 12, pp. 3079–3085, 2017.
- [60] Y. Sushko, S. Novotarskyi, R. Körner, J. Vogt, A. Abdelaziz, and I. V. Tetko, "Prediction-driven matched molecular pairs to interpret qsars and aid the molecular optimization process," *Journal of Cheminformatics*, vol. 6, no. 1, pp. 1–18, 2014.
- [61] A. G. Leach, H. D. Jones, D. A. Cosgrove, P. W. Kenny, L. Ruston, P. MacFaul, J. M. Wood, N. Colclough, and B. Law, "Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure," *Journal* of medicinal chemistry, vol. 49, no. 23, pp. 6672–6682, 2006.
- [62] X. Hu, Y. Hu, M. Vogt, D. Stumpfe, and J. Bajorath, "Mmp-cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs," *Journal of chemical information and modeling*, vol. 52, no. 5, pp. 1138–1145, 2012.
- [63] D. Stumpfe, H. Hu, and J. Bajorath, "Computational method for the identification of third generation activity cliffs," *MethodsX*, vol. 7, p. 100793, 2020.
- [64] H. Hu and J. Bajorath, "Introducing a new category of activity cliffs combining different compound similarity criteria," *RSC Medicinal Chemistry*, vol. 11, no. 1, pp. 132–141, 2020.
- [65] I. Lukac, J. Zarnecka, E. J. Griffen, A. G. Dossetter, S. A. St-Gallay, S. J. Enoch, J. C. Madden, and A. G. Leach, "Turbocharging matched molecular pair analysis: optimizing the identification and analysis of pairs," *Journal of Chemical Information and Modeling*, vol. 57, no. 10, pp. 2424–2436, 2017.
- [66] Y. Hu and J. Bajorath, "Extending the activity cliff concept: structural categorization of activity cliffs and systematic identification of different types of cliffs in the chembl database," *Journal of chemical information and modeling*, vol. 52, no. 7, pp. 1806–1811, 2012.
- [67] S. Tamura, S. Jasial, T. Miyao, and K. Funatsu, "Interpretation of ligandbased activity cliff prediction models using the matched molecular pair kernel," *Molecules*, vol. 26, no. 16, p. 4916, 2021.
- [68] J. Park, G. Sung, S. Lee, S. Kang, and C. Park, "Acgcn: Graph convolutional networks for activity cliff prediction between matched molecular pairs," *Journal of Chemical Information and Modeling*, 2022.
- [69] J. Iqbal, M. Vogt, and J. Bajorath, "Prediction of activity cliffs on the basis of images using convolutional neural networks," *Journal of Computer-Aided Molecular Design*, vol. 35, no. 12, pp. 1157–1164, 2021.
- [70] S. Tamura, T. Miyao, and K. Funatsu, "Ligand-based activity cliff prediction models with applicability domain," *Molecular Informatics*, vol. 39, no. 12, p. 2000103, 2020.

- [71] D. Horvath, G. Marcou, A. Varnek, S. Kayastha, A. de la Vega de Leon, and J. Bajorath, "Prediction of activity cliffs using condensed graphs of reaction representations, descriptor recombination, support vector machine classification, and support vector regression," *Journal* of Chemical Information and Modeling, vol. 56, no. 9, pp. 1631–1640, 2016.
- [72] D. Dimova, K. Heikamp, D. Stumpfe, and J. Bajorath, "Do medicinal chemists learn from activity cliffs? a systematic evaluation of cliff progression in evolving compound data sets," *Journal of Medicinal Chemistry*, vol. 56, no. 8, pp. 3339–3345, 2013.
- [73] D. Stumpfe, Y. Hu, D. Dimova, and J. Bajorath, "Recent progress in understanding activity cliffs and their utility in medicinal chemistry: miniperspective," *Journal of medicinal chemistry*, vol. 57, no. 1, pp. 18–28, 2014.